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ABSTRACT
The purpose of this study was to discover antimalarial compounds from necrotropic plant
pathogenic fungi. Various phytotoxins released by necrotropic plant pathogenic fungi may
inhibit the plant-like metabolic pathways in the apicoplast, a chloroplast-like organelle, essential
for the survival of apicomplexan parasites, such as Plasmodium which cause malaria in humans.
This dissertation describes the isolation, characterization, and biological evaluation of secondary
metabolites of eight fungal strains. In addition to the antiplasmodial assay, all the extracts were
subjected to phytotoxic, antimicrobial, and cytotoxic bioassays. Isolation of metabolites was
performed by chromatographic methods and identification was carried out by spectroscopic and
spectrometric methods. Absolute configurations of the metabolites were determined by
comparing specific rotation values, ECD spectra, or X ray crystallographic analysis.
The dissertation consists of seven chapters. Chapter 1 describes the overview of the
current malaria situation in the world and the rationale for using necrotropic plant pathogenic
fungi to discover antimalarial leads. Protocols used for isolation and fermentation of endophytic
fungi from infected plant parts, as well as those used for biological activities of fungal
metabolites are described in Chapter 2. Chapters 3-6 describe the isolation and identification of
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metabolites from the plant pathogenic fungi obtained from the American Type Culture
Collection (ATCC) (Septoria pistaciarum, S. musiva, Phomopsis viticola, and Postia balsamea).
Chapter 7 consists of four sections which describe the isolation and identification of
active metabolites from four endophytic fungi (Xylaria sp., Alternaria sp., Botryosphaeria
dothidea, and a new fungus, UM #10 M) isolated from the infected leaves and seeds of Torreya
taxifolia.
From these fungi, 40 compounds including 17 new natural products were isolated and identified.
Thirteen compounds displayed antiplasmodial activity, 12 showed phytotoxicity, whereas all 13
exhibited weak to moderate cytotoxicity towards mammalian cells. This indicates that
cytotoxicity rather than inhibition of plant-like metabolic pathways in the apicoplast was
probably responsible for the observed antiplasmodial activity.
The antiplasmodial compounds with high selectivity indices, septoriamycin A and 19,20epoxycytochalasin C, were evaluated for antimalarial activity in a mouse model. Septoriamycin
A showed no activity or toxicity, whereas 19,20-epoxycytochalasin C, exhibited toxicity and
weak suppressive activity.
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CHAPTER 1: INTRODUCTION
ANTIMALARIALS FROM PLANT PATHOGENIC FUNGI

1.1. Background and Significance

Malaria is an infectious disease caused by apicomplexan parasites of the genus
Plasmodium that are transmitted to people through bites of infected Anopheles mosquitoes. This
disease is endemic throughout the tropics, especially in sub-Saharan Africa and the developing
world, threatening about 40% of the world’s population.1 More than 200 million cases of
malaria and around 650,000 deaths, the majority of them African children, have been reported in
2010.1
Human malaria is caused by Plasmodium falciparum, P. vivax, P. ovale, and P. malariae.
P. falciparum and P. vivax are the most prevalent, and P. falciparum is responsible for the
majority of mortality. P. vivax, P. ovale, and P. malariae cause a mild form of the disease, and P.
knowlesi, a zoonosis, also rarely infects humans. Owing to the unavailability of effective
vaccines, pharmacotherapy is still the only mode of therapy for malaria.2 Several drugs, synthetic
and natural product-derived, are currently available for the treatment of malaria;2,

3

however,

control of this disease is limited by drug resistance in the parasite and insecticide resistance in
1

the mosquito vector.3 Resistance to all available drugs except artemisinin has been reported
from many malaria endemic areas. Recent studies indicate the emergence of strains in Cambodia
also resistant to artemisinin derivatives.4 No new class of antimalarials has been approved since
1996,3 therefore, there is an urgent need to develop drugs with new modes of action to counter
this trend.

1.2. The Apicoplast as an Antimalarial Drug Target

The apicoplast is an organelle essential for the survival and viability of the apicomplexan
parasites such as Plasmodium, Toxoplasma, Theileria, Babasia, and Eimeria (Figure 1.1). This
organelle is similar to plastids found in the cells of photosynthetic organisms like algae and
plants.5 Plastids are present in plants in several forms such as chloroplasts, leucoplasts,
amyloplasts, and chromoplasts with the same genetic compliments.6 It is believed that
apicomplexan parasites acquired the apicoplast by engulfment of an ancestral algae and retention
of its plastid.5 Apicoplasts contain their own genome that encodes for prokaryotic protein
synthesis (70 S ribosomes, tRNAs, RNA polymerase, and DNA gyrase) and a small number of
proteins.7 Many biosynthetic pathways in apicoplasts, including heme and ion sulfur clusters,
type II fatty acid synthase, and the non-mevalonate pathway for isoprenoids, are absent in the
vertebrate hosts of parasites, but are similar to those present in the plastids of plants (Table 1.1).5,
6, 8

Apicoplast function is essential for both erythrocytic and hepatic development of the

plasmodia parasites in mammalian hosts;7 thus, metabolic pathways found in apicoplasts are
good targets for antimalarial drug discovery.5 Research over the last decade has demonstrated a
2

number of validated targets in plant-like metabolic pathways in the apicoplast of malaria
parasites.5, 7, 9, 10

Figure 1.1. General features of apicomplexan cells11

(Reprinted by permission from Nature Publishing Group)
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Table 1.1. Drugs and possible apicoplast targets5, 10

Drug/herbicide

Metabolic activity

Putative target

Ciprofloxacin

DNA replication

Plastid DNA topoisomerase II

Clindamycin

Protein translation

Plastid 23S rRNA

Erythromycin
Azithromycin
Spiramycin
Thiostrepton
Micrococcin
Chloramphenicol
Doxycycline

Plastid 16S rRNA

Tetracycline
Elongation factor Tu (thermo
Amythiamicin
Rifampicin

unstable)
RNA transcription

Plastid RNA polymerase β-subunit

Fosmidomycin

Isoprenoid biosynthesis

DOXP reductoisomerase

Thiolactomycin

Fatty acid biosynthesis

Β-ketoacyl-ACP synthase (Fab H)

Clodinafop

Fatty acid biosynthesis

Acetyl-CoA carboxylase (ACC)

Triclosan

Fatty acid biosynthesis

Enoyl-ACP reductase (Fab I)
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Antibiotics such as azithromycin, doxycycline, clindamycin, tetracyclines, rifampicin,
and fluoroquinolones which are used for prophylaxis and treatment of malaria in combination
with other antimalarial drugs,7 have been reported to target apicoplast prokaryotic derived
protein translation pathways.5,7,12 Isoprenoid biosynthesis of the apicoplast involves the nonmevalonate pathway which is similar to that in bacteria, and is known as the 1-deoxy-Dxylulose-5-phosphate (DOXP) or 2-C-methyl-D-erythritol-4-phosphate (MEP)pathway.6 Unlike
in humans, these isoprenoids are prosthetic groups for many enzymes involved in apicoplast
translation, synthesis of mitochondrial ubiquinones, protein prenylation, and the formation of
dolichols which are also involved in membrane proteins of the parasite.6 Fosmidomycin, an
inhibitor of DOXP reductoisomerase (IspC) of isoprenoid biosynthesis in the apicoplast has
been reported to be effective in killing in the intra-erythrocytic phase of the malaria parasite.6
Tonhosolo et al.13 also reported the presence of carotenoid biosynthesis including the phytoene
desaturase enzyme in the apicoplast of the intraerythrocytic stages of P. falciparum. Inhibition of
parasite growth by the herbicide norflurazon, a phytoene desaturase inhibitor, and chemical
rescue by lycopene clearly indicated that this pathway is also a potential target for antimalarial
drug therapy.13 Recent findings of chemical rescue of blood stage P. falciparum lacking an
apicoplast demonstrated that parasites also exclusively depend on the apicoplast for isoprenoid
precursors, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).14 In
contrast to humans and other eukaryotes without plastids, the apicoplast of the malaria parasite
uses bacterial type fatty acid II synthase for the synthesis of lipids required for its function and to
form parasitoporous vacuoles (PV) for the invasion of host erythrocytes.5 Apicoplast fatty acid II
synthase biosynthesis involves several distinct enzymes namely, acetyl-CoA carboxylase (ACC),
5

acyl carrier protein transacylase (FabD), β-ketoacyl-ACP synthase (FabH), β-ketoacyl-ACP
synthase (FabB/F), β-ketoacyl-ACP reductase (FabG), β-hydroxyacyl-ACP dehydratase
(FabZ/A) and trans-2-enoyl-ACP reductase (FabI).15 All these enzymes are potential targets for
malaria drug discovery.15, 16 FabH inhibitors like cerulenin, platensimycin,17 thiolactomycin, and
their analogues,18 and FabI inhibitors triclosan,18 and (E)-oroidin,19 many of these of natural
origin, have been reported to have herbicidal and antimalarial activities.5, 9 Several attempts have
also been made in designing and in silico screening of analogues of

triclosan,16,

20

and

thiolactomycin,18 as well as flavonoid derivatives21 for the antimalarial FAS-II activity.
The apicoplast of the malaria parasite also possesses a family of class II histone
deacetylase (HDAC) proteins which are also present in other photosynthetic eukaryotes and
primitive algae.22 The enzyme CpHDAC3 (Rpd3 super family classs II) catalyzes deacetylation
of histone tails to promote epigenetic regulation and some cellular processes of the parasite.22-24
Analogues of several known anticancer HDAC inhibitors, such as suberoylanilide hydroxamic
acid (SAHA), SB 939, hydroxamic acid (TSA), and apicidin have shown activity against the
malaria parasite, some at low nanomolar concentrations.23, 25-30
It has been demonstrated that all these apicoplast specific pathways are important for its
proper functioning. Plasmodium parasites exclusively depend on the apicoplast for isoprenoid
precursors, and it is involved in establishing the parasitophorus vacuole in host cells and invasion
of parasites in new host cells.6,

9, 14

Thus, plant-like metabolic pathways in the apicoplast are

potential targets for malaria drug discovery.
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1.3. Plant Pathogenic Fungi

Fungi produce a variety of biologically active secondary metabolites with applications in
agriculture and medicine.31 Endophytic fungi reside inter- and-/or intracellularly in plants and
their association can vary from latent pathogenesis to mutualistic symbiosis.31,32 Many
endophytic fungi are inert phytopathogens which cause disease symptoms when the host plant is
aged and/or stressed under various environmental conditions.33 Phytopathogenic fungi are
ubiquitous in the plant kingdom and their diversity depends on the ecosystem and host species.
Plant pathogenic fungi are grouped into three categories based on their mode of nutrition. 34, 35
Biotrophs derive their nutrients from the host plant without killing it, whereas necrotrophs kill
host plant cells to derive their nutrition.34 Hemi-biotrophs have an initial biotrophic phase and
then gradually become necrotrophic.35 Some biotrophs have symbiotic as well as parasitic
associations.35 Parasitic biotrophic fungi such as rusts, smuts, and mildew have a restricted host
range.35 In general, necrotrophs have a broader host range than biotrophs.36
The invasion of host cells by necrotrophic fungi with appressoria and haustoria is
initiated by active penetration of the surface by germinating fungal spores in favorable
environmental conditions.37 The fungi release degradative enzymes such as pectinases,
cellulases, proteases, and toxins to kill host cells.37 Wood-rotting pathogenic fungi preferentially
attack living trees and rapidly depolymerize the cell wall components of internal, vascular, and
cambium tissues.34 Host cells activate plant defense mechanisms by releasing phytoalexins,
antifungal pathogenesis related proteins (PR’s), and oxidative enzymes.38 The spread of the
7

pathogen is controlled by an effective host defense mechanism;39 however, most of the plant
pathogenic fungi (necrotrophs) can overcome the host defense mechanisms and derive nutrition
by killing the neighboring cells. According to Schulz and Boyle’s hypothesis 39 (Figure 1.2), as
long as fungal virulence and host defense are balanced, colonization remains asymptomatic.39
When the balance is disturbed by environmental factors or by senescence in favor of the fungus,
disease develops.39 Pathogenesis is associated with the amount of phytotoxin produced by the
pathogen.

Figure 1.2. Host-fungi interaction39
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Degradative enzymes and/or toxins released into host cells by necrotrophic fungi cause
necrotic lesions, chlorosis, wilting, and finally death of plant parts.40 Necrotrophic disease is
recognized by patches of dead black tissues and identified by different names such as
anthracnose, blight, canker, scab, leaf spot, fruit rot, heart rot, butt rot, root rot, and shot hole.34
Unlike biotrophs, necrotrophs can survive in the absence of their host cells and thus can be
cultivated in an artificial media to isolate the biologically active lead molecules.
Some natural and synthetic phytotoxic compounds have been shown to target the plantlike metabolic pathways in the plastid of plants, indicating their potential as inhibitors of
metabolic pathways in the apicoplast of malaria parasites.41

1.4. Fungi as a Source of Antimalarials

Natural products have been used as antimalarial drugs or pharmacophores in designing
potent analogues. Quinine, artemisinin, doxycycline, clindamycin, and azithromycin are some of
the currently used malaria drugs that have been isolated from plants or microorganism.42 Fungal
metabolites have several advantages over plant secondary metabolites: large scale preparation of
metabolites can be carried out without disturbing biodiversity; optimization can be done using
genetic engineering approaches; and results can be obtained in a short time, in many cases in less
than one month, reducing the cost and time of drug development processes. Endophytic fungi,
including necrotrophic plant pathogenic fungi, have yielded a number of metabolites with a
variety of biological activities including antimalarial activity;31 however, antimalarial fungal
9

metabolites may also act on targets other than those in the apicoplast such as cytosolic targets
(dihydrofolate reductase inhibitors), food vacuole targets (haemozoin inhibitors), and membrane
targets (biosynthesis and transport of phospholipids).5, 43
Recently, several antimalarial compounds have been isolated and identified from fungi
and some of these compounds can be considered potential therapeutic agents. A Scifinder
Scholar® survey on antimalarials reported from endophytic, insect pathogenic, and plant
pathogenic fungi showed a number of active compounds. These compounds are chemically
diverse and showed varying degrees of antiplasmodial and cytotoxic activities (Table 1.2 &
Figure 1.3). Of these compounds, radicicol (30) was moderately active in vivo at 40 mg/kg and
heptelidic acid (31) showed hemolysis at this dose.

Table 1.2. Antimalarials reported from fungi

Fungi

Compounds

Activity/µM

Cytotoxicity

Ref.

Menisporopsis theobromae

Menisporopsin A (1)

5.0

Cytotoxic

44

Menisporopsis theobromae

Dithiodiketopiperazine (2)

2.95

Weak

45

Cordyceps brunnearubra

Cordyformamide (3)

18

Weak

46

Paecilomyces cinnamomeus

Paecilodepsipeptides (4)

4.9

Cytotoxic

47

Hirsutella nivea

Hirsutatins B (5)

8.2

Not toxic

48

Phomopsis sp.

Phomoxanthones A (6)

0.14

Cytotoxic

49

Phomoxanthones A (7)

0.44

Cytotoxic

9-Methoxystrobilurin B (8)

0.85

Weak to

9-Methoxystrobilurin G (9)

0.06

moderate

Cordycepin (11)

17.8

Not reported

Favolaschia tonkinensis

Cordyceps militaris

10

50

51

Geotrichum sp.

Dihydroisocoumarin (12)

8.4

Not reported

52

Hirsutella kobayasii

Hirsutellide A (13)

4.2

Non toxic to

53

vero
Kionochaeta pughii

Pughiinin A (14)

6.7

Not toxic

Picnidione (15)

0.5

Cytotoxic

Microsphaeropsis sp.

Preussomerins (16)

2.3

Cytotoxic

Xylaria sp.

(-)-Depudecin (17)

4.7

Cytotoxic

(+)-Phaseolinone (18)

1.7

Cytotoxic

(+)-Phomenone (19)

1.2

Cytotoxic

19,20-Epoxycytochalasin Q

1.1

Cytotoxic

54,55

56

57

(20)
Sclerotinia homoeocarpa

Tetranorditerpenoids (21)

0.1

Cytotoxic

58

Rhizina sp.

Chromanone

14.7

Moderate

59

derivatives

(22)
Berkleasmium nigroapicale

Berkleasmin (23)

5.4

Cytotoxic

60

Torrubiella luteorostrata

Pyrone diterpene (24)

8.1

Cytotoxic

61

Penicillium sp.

Brefeldin A (25)

3.9

Cytotoxic

62

Myrothecium verrucaria

Macrocyclic trichothecenes
Roridin E acetate (26)

0.0001

Cytotoxic

63

Cordypyridones A (27)

0.23

Weak

64

Cordypyridones B (28)

0.13

Weak

Streptomyces sp.

Nanomycin A (29)

0.03

Weak

65, 66

Humicola sp.

Radicicol (30)

0.02

Weak

67

Soil fungus- FO-4443

Heptelidic acid (31)

0.04

Weak

Cordiceps nipponica

11

12

13

Figure 1.3: Antimalarial compounds reported from fungi
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1.5. Aims and Objectives of the Thesis

Malaria, an infectious disease caused by Plasmodium parasites, is a major cause of
morbidity and mortality in tropical parts of the world. Control of this disease is hampered by
drug resistance. No new class of antimalarial drug has been approved since 1996.
The overall aim of this project is to search for antimalarial compounds from necrotrophic
plant pathogenic fungi based on the rationale that certain phytotoxins biosynthesized by this
class of fungi may inhibit plant-like metabolic pathways in the apicoplast, an essential organelle,
of the apicomplexan parasites including Plasmodium.

Main objectives were:
1.5.1. Procurement of necrotrophic plant pathogenic fungi
1.5.2. Culture and extraction of fungi
1.5.3. Evaluation of fungal extracts for herbicidal and antiplasmodial activities
1.5.4. Bioassay guided fractionation of active extracts and isolation of compounds responsible
for biological activity.
1.5.5. Identification of actives compounds
1.5.6. Evaluation of promising active compounds in animal models

15

CHAPTER 2: MATERIALS AND METHODS

The overall approach of this research project as summarized in Figure 2.1 was to search for
antimalarial actives from necrotrophic plant pathogenic fungi based on the rationale that some
phytotoxins released by these fungi may inhibit plant-like metabolic pathways in the apicoplast,
an essential organelle, of the apicomplexan parasites.

2.1. Sources of Necrotrophic Plant Pathogenic Fungi

ATCC (American Type Culture Collection): The ATCC database was searched for fungi
which caused leaf spot, fruit rot, heart rot, butt rot, and root rot diseases in plants and the
available organisms were purchased.
Plant pathology labs: Identified plant pathogenic fungi were obtained from the Biological
Control of Pests Research Unit, USDA-ARS, Stoneville, MS 38677, USA and the Center for
Bottomland Hardwoods Research, USDA-Forest Service, Southern Hardwoods Laboratory,
Stoneville, MS 38677, USA.

16

Fresh necrotropic plant-pathogenic fungal isolates from infected plant: Leaves which
showed cell death (leaf spots) due to fungal infections were collected from cultivated plants and
fungi were isolated from infected leaf areas.

Phytopathogenic fungi

Imidazo pyridine and pyrimidine
Plant pathology labs

ATCC

Fresh isolates

derivatives

Fermentation and extraction of metabolites
Imidazo pyridine and pyrimidine derivatives
In vitro antiplasmodial assay

In vitro cytotoxicity assay

In vitro phytotoxicity assay

Bioassay guided fractionation
New leads

In vivo antimalarial assay

& structure elucidation
totoxicity assay

New targets

New antimalarials

Figure 2.1. The overall design of the research approach
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2.2. Isolation of Fungi from Infected Plant Materials

Leaves of the infected plant, Torreya taxifolia Arnott, were obtained from Dr. Edward
Croom. The plant species identity was determined by Dr. Croom following the taxonomic
treatment in the Flora of North America
(http://www.efloras.org/florataxon.aspx?flora_id=1&taxon_id=220013607).

2.2.1. From Infected leaves

The infected parts of leaves were surface-sterilized with 5% Clorox for 5 minutes and
rinsed with sterile water (×3). Transverse sections from the dried leaf were cut aseptically into
small portions and immersed into Potato Dextrose plates (PDA). Plates were incubated for two
weeks and sub-cultured to PDA plates to isolate pure fungal strain.

2.2.2. From Infected seeds

Infected seeds of T. taxifolia Arnott were furnished by Dr. Edward Croom, Croomia,
1509, Smallwood Dr., Oxford, MS, and isolation of fungi from those was performed by Dr.
Luis Rosa, NCNPR, University of Mississippi.
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2.3. Identification of Fungi

DNA sequence analysis of fungi was carried out68 by Dr. N. Techen, NCNPR,
University of Mississippi
Preliminary identification of isolated fungi were mainly based on morphological features
of colonies and DNA sequence analysis of internal transcribed spacer (ITS) regions of nuclear
ribosomal DNA (nrDNA).

2.4. In Vitro Culture and Extraction of Plant Pathogenic Fungi

Pure fungal isolates were grown in PDA plates at 27 ºC for 5-7 days. For preliminary
assays, fungi were cultured in 2 conical flasks (1 L) containing 500 mL of potato dextrose broth
and incubated at 27 ºC for 2 weeks, 3 weeks, and 4 weeks respectively, on an orbital shaker.
Culture medium was separated by filtration and mycelium and broth were extracted with EtOAc
(× 3). Fungi which showed antiplasmodial activity were cultured in large scale (20 L, 40 L)
media to obtain sufficient amount of extracts. If a fungal extract showed no activity in the
antimalarial bioassay, then the fungus was cultured in three additional media selected from the
following:
1. PDB
2. Modified Czapex Dox Broth
3. Solid media (Rice)
19

4. V – 8 (100% vegetable juice)

2.5 Evaluation of In vitro Antimalarial and Phytotoxic Activities of the Extracts

Mycelium and broth extracts were subjected to in vitro antiplasmodial (10.0 mg each) and
phytotoxic (1.0 mg of each) assays. Metabolites which inhibit plant-like metabolic pathways in
the apicoplast should exhibit both antimalarial and phytotoxic activities. However, cytotoxic
compounds also may show positive results in both of these assays. In order to identify these
compounds, extracts were also simultaneously evaluated for cytotoxicity and selectivity indices
(IC50 cytotoxicity / IC50 antiplasmodial activity). Active extracts with good selectivity indices
(>10) were selected for bioassay-guided fractionation.
2.6. Bioassay Guided Fractionation of Antimalarial Extracts, Isolation, and Structural
Elucidation of Bioactive Metabolites.

Active extracts were fractionated using chromatographic methods. A suitable stationary
phase was selected on the basis of the chemical profile of the extract. For preliminary
fractionation, gel filtration, reversed-phase, or normal phase column chromatography was used.
Further separation of active fractions was carried out by the same methods and also by
preparative TLC and HPLC. Structure elucidation of active compounds was carried out by
spectroscopic/spectrometric methods (UV/Visible, IR, 1H, 13C, NMR, COSY, NOESY/ROESY,
HMQC, HMBC, and HRMS). Absolute configuration was determined by comparing specific
rotation values, ECD spectra, or X ray crystallography.
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Out of the broth and mycelia extracts of 60 plant pathogenic and endophytic fungi
screened in different culture media, the extracts as shown in Table 2.1 showed good
antiplasmodial and herbicidal activities. Among them the following fungal strains were selected
for further isolation and characterization of bioactive metabolites
1. Septoria pistaciarum (Chapter 3 & 4)
2.

Septoria. musiva (Chapter 5)

3. Phomopsis viticola (Chapter 5)
4. Postia balsamea (Chapter 6)
5. Xylaria sp. (Chapter 7 section 1)
6. Alternaria sp. (Chapter 7 section 2)
7.

UM #10 M (new isolate) (Chapter 7 section 3)

8. Botryosphaeria dothidea (Chapter 7 section 4)
These extracts were also screened for antimicrobial and antileishmanial activities.
Among those, some of plant pathogenic fungal extracts (Sclerotinia homeocarpa, Gleosporium
minus, Elsinoe corni, Resinium bicolor) and an unidentified endophytic fungus (# 1 A) isolated
from cultivated Torreya taxifolia Arnott showed good antimicrobial activities.

2.7. Preparation of Culture Media

2.7.1. Potato Dextrose Broth (PDB)
24.0 g of PDB powder (DifcoTM)
1.0 L of distilled water
21

PDB powder and a magnet was added to an Erlenmeyer flask (1L) containing 1 L of distilled
water and heated at boiling point on a stirrer for about 15 minutes. The solution was divided
into two Erlenmeyer flasks (500 mL). Flasks were covered with Aluminum foil and then
autoclaved at 121 οC for 15 minutes.

2.7.2. Modified Czapex Dox Broth

Czapex Dox 35 g
Yeast 1.5 g
Malt extract 1.5 g
All ingredients were dissolved in 1 L of distilled water and autoclaved at 121 0C for 15 minutes.

2.7.3. Solid Media (Rice)

Rice (long grain) 100 g
Distilled water 60 mL
Rice was mixed with distilled water in an Erlenmeyer flask and was allowed to stand for 2
hours. Then it was autoclaved at 121 οC for 45 minutes. After 24 hours, flasks were reautoclaved under the same conditions, and allowed to cool to room temperature.
inoculated into PDB media were used to inoculate these solid media.
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Fungi

2.7.4. V-8 ( 100% vegetable juice)

V-8 100 mL
PDB 12 g
CaCO3 1.5 g
All ingredients were dissolved in 1 L of distilled water and autoclaved at 121 ºC for 15 minutes.

2.7.5. Potato Dextrose Agar (PDA) plates

39.0 g of PDA powder (DifcoTM)
1.0 L of double deionized (DDI) water
PDA powder with a small magnet was added to an Erlenmeyer flask (2L) containing 1 L of
distilled water and heated at boiling point on a stirrer for about 15 minutes. The solution was
divided into two Erlenmeyer flasks (500 mL). The flasks were covered with aluminium foil and
then autoclaved at 121 οC for 15 minutes. This media were used to pour into sterilized
petridishes and allowed to solidify over 5 minutes.
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Table 2.1. Antiplasmodial and herbicidal activity of plant pathogenic fungi extracts

Antiplasmodial activity IC 50 (ng/mL)

Cytotoxicity

Phytotoxicity

(Vero)
Fungi

Medium

Septoria pistaciarum (Broth +

Czapex

mycelium)

Dox

IC 50 (ng/mL)
P. falciparum D6

SI

P. falciparum W2

SI

1200

3.1

1400

2.6

Lettuce

Bentgrass

3700

5

5

Czapex

24

S. musiva (Broth + Mycelium )

Dox

720

4.2

570

5.3

3000

5

5

Postia balsamea (Broth)

PDB

1800

25

1400

32.1

45000

5

5

Phomopsis viticola (Broth )

PDB

11000

>4.3

10000

>4.8

NC

NT

NT

Phomopsis viticola (Broth )

V8

1200

>39.7

1200

>39.7

NC

NT

NT

Czapex
Phomopsis viticola (Broth)

Dox

570

83.5

400

119

47600

5

5

Sclerotinia homoeocarpa (Broth)

PDB

700

28.6

1300

15.4

20000

5

5

Amylostereum ferreum (Broth)

PDB

3000

>15.9

2300

>20.7

NC

NT

NT

Amylostereum laevigatum (Broth)

PDB

2400

>19.8

1700

>28

NC

NT

NT
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Botryosphaeria dothidea (Broth)

PDB

860

37.2

1300

24.6

32000

5

5

Xylaria sp (Broth)

PDB

62

3.3

87

2.3

200

5

5

UM #10 M (Broth)

PDB

40

170

44

154.5

6800

5

5

PDB

6800

1.8

5800

2.1

12000

5

5

Alternaria sp. (Broth +
Mycelium)

Antiplasmodial assay: NC = not cytotoxic , NT = not tested , S. I. (selectivity index) = IC 50 for cytotoxicity /IC50 for
antiplasmodial activity, IC50: concentration causing 50% growth inhibition, Phytotoxicity assay: Concentration (mM) = 1
mg/mL, Ranking based on scale of 0 to 5, 0 = no effect, 5 = no growth
25
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2.8. Preparation of Stock Solution (10 % RPMI Buffer Solution) for Long Term Storage of
Fungi

2.8.1. RPMI (Roswell Park Memorial Institute) Buffer Preparation

Powdered medium of RPMI 1640 without sodium bicarbonate (10.4 g) was mixed with
34.5 g of MOPS (3-(N-Morpholino)propanesulfonic acid) buffer in a beaker (1L) and dissolved
in 750 mL of DDI water. The pH was adjusted to 7.0 with 0.1M NaOH and DDI water was
added and stirred to bring the total volume to 1.0 L. RPMI BUFFER was filtered using a 0.45
micron filter unit to sterilize and stored at 4 ºC.

2.8.2. 10% Glycerol/RPMI Buffer Stock Solution

90 mL of RPMI buffer (Stock buffer stored at 4 οC) and 10 mL of glycerol were vortexed
for 2 minutes. It was filtered using Nalgene® (NYL) filter unit, (0.45 micrones, 250 mL), and
stored at 4 0C.

2.8.3. Inoculum Stock Solution

50 µL of inoculum was added to 1 mL of 10% RPMI buffer/glycerol stock solution in a 5
mL round bottom tube, vortexed and stored at 4 οC.
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2.8.4. Select Isolate for Storage

Fungal spores were scraped from the PDA plates (4-5) with sterilized DDI water. Spore
suspension was filtered through a mirror cloth and collected into a polypropylene conical tube,
mixed with a vortex and stored at 4 οC. After 24 hours, supernatant was removed. 5 mL of 10%
glycerol/ RPMI buffer stock was added on to spores and vortexed for 2 minutes. 0.5 mL conidial
suspension was added into each cryogenic vial and stored at -80 οC.

2.9. Evaluation of Pure Compounds for In Vitro Biological Activities

Pure compounds (2.0 mg each) were submitted to the National Center for Natural
Products Research (NCNPR) for screening of antimalarial, cytotoxic, antimicrobial (antifungal
and antibacterial), and antileishmanial activities.
2.9.1. In Vitro Antiplasmodial Screening

This assay was performed by Dr. S. Khan, NCNPR. University of Mississippi
The antiplasmodial activity of extracts, fractions, and pure compounds was performed against D6
(chloroquine sensitive) and W2 (chloroquine resistant) strains of P. falciparum using the in vitro
assay as reported.69 The 96-well microplate assay was based on evaluation of the effect of
compounds/extracts on growth of asynchronous cultures of P. falciparum, determined by the
assay of parasite lactate dehydrogenase (pLDH) activity. The appropriate dilutions of the
compounds /extracts were prepared in DMSO or RPMI-1640 medium and it was added to the
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cultures of P. falciparum (2% hematocrit, 2% parasitemia) set up in clear flat bottomed 96 well
plates. The plates were placed into the humidified chamber and flushed with a gas mixture of
90% N2, 5% CO2, and 5% O2. The cultures were incubated at 37 οC for 72 hours. The growth of
the parasite in each well was determined by pLDH assay using Malsatat® reagent. The medium
and RBC controls were also set-up in each plate. In addition to the P. falciparum strains, samples
were tested against mammalian kidney cell line (Vero) as an indicator of general cytotoxicity.
The selectivity indices (SI) – ratio of Vero IC50 to D6 or W2 IC50 – were calculated.
Artemisinin and chloroquine were used as the positive controls while DMSO was the negative
control. IC50 values were computed from the dose response curves using Microsoft Excel
software.
2.9.2. In Vitro Phytotoxicity Activity

This assay was performed by Dr. S. Duke, USDA-ARS, University of Mississippi.
Herbicidal or phytotoxic activity of extracts and test compounds was performed via the
published procedure70 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa cv. L.,
Iceberg), in 24-well plates. Test compounds (1 mg each) were dissolved in 100 µL of acetone
and a 20 µL aliquot of each solution was pipetted onto the filter paper and dried for 30 min under
airflow in a sterile biohazard hood. Water (200 µL) was added after placing the dried and sample
impregnated filter paper in the well. The solvent controls were treated identically, using the
solvent described above. Phytotoxicity was ranked visually. The ranking of phytotoxic activity
was based on a scale of 0 to 5 with 0 showing no effect and 5 no growth.
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2.9.3. In Vitro Antimicrobial Activity

This assay was performed by Dr. M. Jacob, NCNPR, University of Mississippi.
All organisms were obtained from the American Type Culture Collection (Manassas,
VA) and include the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei
ATCC 6258, Cryptococcus neoformans ATCC 90113 and Aspergillus fumigatus ATCC 90906
and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant Staphylococcus
aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC
27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing was performed
using a modified version of the CLSI methods71,

72

as described.73 M. intracellulare and A.

fumigatus growth were monitored using Alamar BlueTM (Bio-Source International, Camarillo,
CA). Samples dissolved in DMSO were serially diluted using 0.9% DMSO and transferred in
duplicate to 96 well flat bottom microplates. Microbial inocula were prepared by diluting saline
suspensions of colonies with assay broth to afford recommended colony forming units/mL.
Growth (saline only), solvent and blank (media only) controls were included on each test plate.
The drug controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B (ICN
Biomedicals, Ohio) for fungi were included in each assay. All organisms were read at either 630
nm using the EL-340 Biokinetics Reader (Bio-Tek Instruments, Vermont) or 544ex/590em (M.
intracellulare, A. fumigatus) using the Polarstar Galaxy Plate Reader (BMG Lab Technologies,
Germany) prior to and after incubation. The MIC (minimum inhibitory concentration) was
defined as the lowest test concentration that allowed no detectable growth.
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2.9.4. In Vitro Antileishmanial Assay

This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi.
The in vitro antileishmanial activity of the isolated compounds was carried out on a culture of
Leishmania donovani promastigotes and axenic amastigotes by the Alamar Blue assay as
described.74 In a 96 well microplate the samples with appropriate dilution were added to the
leishmania promastigotes/axenic amastigote culture (2×106 cell/mL). The compounds were
tested at six concentrations ranging from 40 to 0.0128 µg/mL. The plates were incubated at 26
C for 72 hours (37 C for amastigote) and growth of leishmania promastigotes/ amastigotes was
determined. IC50 and IC90 values were computed from the dose response curves. Pentamidine
and amphotericin B were used as standard antileishmanial agents.

2.9.5. In Vitro Macrophage Amastigote Assay

This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi.
A recently developed75 promastigote rescue assay by Jain et al. was used. The THPI 1
cells (Human acute monocytic leukemia cell line) were maintained in RPMI1640 medium
supplemented with 10% fetal bovine serum (FBS). The cells were prepared prior to each assay
and suspended in RPMI1640 medium with 10 % FBS at the cell density of 2.5 X10 5 cells/mL.
Phorbol 12-myristate 13-acetate (PMA) was added to the cell suspension to achieve final
concentration of 25 ng/mL and cells were seeded onto a clear flat-bottom 96 well plate with 200
µL (5×104 cells) into each well. The plate was incubated in a 5% CO2 incubator at 37 C for at
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least 12 hours for differentiation of the THP1 cells to adherent macrophages. After overnight
incubation the medium from each well was discarded and adherent cells were gently washed at
least twice with serum free RPMI1640 medium. The Leishmania donovani promastigotes culture
was harvested at the stationary phase (metacyclic infective stage) and suspended into RPMI1640
medium with 2% FBS at the density of 2.5×106 cells/mL. The 200 µL of promastigotes (5×105)
culture was added to each well. The plate was further incubated in a 5% CO2 incubator at 37 C
for at least 24 hours to allow infection of macrophages with the Leishmania parasites. After 24
hours the non-adherent macrophages and unattached Leishmania promastigotes were washed off
with serum free RPMI1640 medium. The infected macrophages were further incubated at 37 C
and 5% CO2 in 200 µL RMPI1640 medium and 2% FBS with different concentrations of
standard antileishmanial drugs (pentamidine & amphotericin B) or the test compounds for 48
hours. The control wells with medium, uninfected THP1 cells, infected cells without drugs or
test compounds were set up simultaneously. The cultures were washed off with serum free
RPMI1640 and treated for 30 seconds with 20 µL of 0.05% sodium dodecyl sulfate in
RPMI1640 medium for the release of amastigotes from the infected macrophages. To each well
180 µL of RPMI1640 medium with 10% FBS was added and the plate was further incubated at
26 C for 48 hours to allow transformation of released amastigotes to promastigotes. To each
well 20 L of Alamar blue was added, the plates were incubated at 26 C for 24 hours and read
on a BMG Fluostar microplate reader (BMG Lab Technologies) at excitation wavelength of 544
nm and emission wavelength of 590 nm. Each compound was tested in duplicates at six
concentrations, IC50 and IC90 values were computed from the dose response curves.
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2.9.6. Assay for In Vitro Cytotoxicity

This assay was performed by Dr. S. Khan, NCNPR, University of Mississippi.
In vitro cytotoxicity was determined against a panel of mammalian cells that included
kidney fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral
epidermal carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3)
cells.76 The assay was performed in 96-well tissue culture-treated plates. Cells were seeded to
the wells of 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples at
different concentrations were added and plates were again incubated for 48 h. The number of
viable cells was determined by using Neutral Red dye and IC50 values were obtained from dose
response curves. Doxorubicin was used as a positive control.

2.9.7. Evaluation of In Vivo Antimalarial Assay

This assay was performed by Dr. B. L. Tekwani, NCNPR, University of Mississippi.
Housing of the Animals- The colony bred mice weighing 15 -20 g were used for maintaining
the malaria parasite and also for screening of the test compounds for antimalarial activity. The
mice weighing 10-15 g were procured and kept under quarantine for one week. The animals were
maintained on standard diet and water ad libitum and housed in solid bottom cages. Each cage
had 6 mice and control and untreated mice were housed in separate cages in the same room. All
the animal procedures were conducted under sterile conditions in the laminar flow hood.
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Infection – A group of three to five mice was inoculated intraperitoneally or intravenously with
the Plasmodium berghei infected mouse blood. The parasitemia was monitored from day 5
onwards by preparation of blood smears from a tail nick. These mice were used as donor mice
for infecting a larger batch of mice for in vivo testing. The mice with parasitemia >30% were
anesthetized by i.p. injection of ketamine/xylazine (8 mg and 1.2 mg/Kg). Blood was collected
from the heart in sterile citrated saline. The blood counts were adjusted to 4×107 infected
erythroctes /500 µL by dilution with sterile normal saline. Each mouse

was inoculated

intraparitoneally with 4×107 P. berghei infected erythrocytes in 500 µL of sterile saline.

Treatment –

The mice inoculated with P. berghei infected blood were divided into different

groups with 6 animals in each group, housed in separate cages, were subjected to the treatment
with the test compounds. For multiple dose studies three groups of mice were administered with
the test compounds at different dose levels (ranging between 1-100 mg/Kg) by oral route once
daily for three days. The doses may be decided on the basis of prior information available with
the compounds of similar class. In case of novel compounds in vitro cytotoxity data was used as
the guide for dose selection. One group of postive control was treated with chloroquine (30
mg/Kg) while a group of 6 mice was treated with the vehicle.
The mice were closely monitored for at least one hour after receiving the treatment and also at
least once daily (for recording body weight, movement, and behaviour) till their survival or up
to 28 days post infection (the total duration of the experiment). Parasitemia was monitored on
day 5,7,10, 14, 21, and 28 post infection by preparing the blood smears from tail nick. The level
of parasitemia and mean survival time were compared in treated and vehicle control groups.
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Parasitemia was monitored by preparing the thin blood smears from the tail nick and staining
with Geimsa stain.
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CHAPTER 3: BIOACTIVE 1, 4-DIHYDROXY-5-PHENYL-2-PYRIDINONE
ALKALOIDS FROM SEPTORIA PISTACIARUM

Results presented in this chapter have been published in the following journal.

Kumarihamy, M.; Fronczek, F. R.; Ferreira, D.; Jacob, M.; Khan S. I.; Nanayakkara, N. P. D.
Bioactive 1,4-dihydroxy-5-phenyl-2-pyridinone alkaloids from Septoria pistaciarum J. Nat.
Prod. 2010, 73, 1250–1253
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3.1. Summary

Four new 1,4-dihydroxy-5-phenyl-2-pyridinone alkaloids (1-4) were isolated from an EtOAc
extract of a culture medium of Septoria pistaciarum. The structures of these compounds were
determined by spectroscopic methods, and the absolute configuration of the major compound (1)
by X-ray crystallographic analysis. Compound 1 exhibited moderate in vitro antiplasmodial
(antimalarial) activity against chloroquine-sensitive (D6) and -resistant (W2) strains of
Plasmodium falciparum and cytotoxic activity to Vero cells. Compound 2 was moderately active
against both methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus.

3.2. Introduction

Plant-like metabolic pathways found in the apicoplast,10 a chloroplast-like organelle of
Plasmodium species, have been identified as suitable targets in malaria drug discovery. A
number of herbicides and phytotoxins with known molecular targets in the plastid have been
evaluated for antimalarial activity.77,78,41 Various phytotoxins released by plant pathogenic fungi
are known79,80,81 to inhibit metabolic pathways in the apicoplast.82 As part of our ongoing search
for potential sources of new antimalarial compounds, we have screened a number of plant
pathogenic fungi for antiplasmodial activity.
Septoria pistaciarum (Ascomycetes) is the causative agent of Septoria leaf and fruit spot
disease in pistachio (Pistachia vera) in the US83 and Mediterranean countries.84
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An EtOAc extract of this fungus showed potent herbicidal activity and moderate
antiplasmodial activity against Plasmodium falciparum albeit with low selectivity index. No
previous chemical work has been reported for this species. Structurally diversed chemical
compounds namely, septorine,85 N-methoxyseptorine,85 N-methoxyseptorinol (substituted
pyrazines),86 dihydroisocoumarins,87 mycophenolic acid,87 and mycosporins88 have been
reported from the culture medium of the phytopathogenic fungus Septoria nodorum Berk., a
parasite of wheat. Cordipyridones isolated from the insect pathogenic fungus Cordiceps
nipponica have shown potent antimalarial activity with moderate selectivity.64
Bioassay-guided fractionation of the EtOAc extract led to the isolation of a new 1,4dihydroxy-5-phenyl-2-pyridinone analogue as the active compound. Three additional new but
inactive analogues of the same class were also isolated and identified. Several compounds of this
class such as tenellin, bassianin, funiculosin, sambutoxin, oxysporidinones, cordipyridones,
farinosones, and TMC-69 have been isolated from a number of fungal species and have shown
antibacterial,89,90 antitumor,90 antifungal,89,91 and neurotrophic92 activities.

3.3. Results and Discussion

Compound 1 was isolated as the major active constituent of the EtOAc extract of S.
pistaciarum. The molecular formula of 1 was determined as C22H29NO4 by HRESIMS. The 1H
NMR (Figures 3.1 & 3.2) and COSY spectrum (Figure 3.3) displayed six hydrogens in the
aromatic region consisting of a one-proton singlet and an A2B2C system due to a
monosubstituted phenyl group. The 13C NMR spectra (Figures 3.4 & 3.5) confirmed the presence
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of 22 carbon atoms, which comprised five quaternary, 11 methine, two methylene, and four
methyl carbons. NMR signals in the aromatic region showed close resemblance to those of the
1,4-dihydroxy-5-phenyl-2-pyridinone moiety of the antitumor agent, TMC-69-6H, and its
analogues.90 IR absorptions (3109, 1642 and 1556 cm-1) and UV maxima (207.1, 241.0, and
296.0 nm) of 1 were consistent with those reported for a compound with a 1,4-dihydroxy-2pyridinone moiety.64 In its HMBC spectrum (Figure 3.6), H-2′ and H-6′ (7.49) showed cross
peaks with C-3′ and C-5′ (C128.6), C-4′ (C127.9), C-1′ (C133.4), and C-5 (C114.2), and
H-6 (7.69) with C-2 (C158.0), C-4 (C161.4), C-5 (C114.2), and C-1′ (C133.4)
supporting the partial structure of the substituted pyridinone ring moiety. In the aliphatic region,
the 1H NMR spectrum showed two doublets representing two oxymethine hydrogens, and four
methyl resonances, comprising three doublets and a triplet. The 1H NMR data additionally
indicated the presence of a tetrahydropyrano ring attached to C-3 of the pyridinone ring similar
to TMC-69-6H.90 The H-7 oxymethine doublet (4.72) showed cross peaks in the HMBC
spectrum with C-4 (δC 161.4), C-2 (δC 158.0) C-3 (δC 110.4), C-11 (δC 89.9), C-9 (δC 42.2), C-8
(δC 36.8), and C-15 (δC 17.5). The H-11 oxymethine doublet at 3.07 similarly displayed
HMBC correlations with C-7 (δC 81.4), C-9 (δC 42.2), C-12 (δC 35.6), C-13 (δC 22.1), C-16 (δC
17.5), and C-17 (δC 17.2). The methyl triplet at 0.98 showed HMBC cross peaks with C-12 (δC
35.5) and C-13 (δC 22.0) confirming its ω location in the chain. These correlations strongly
suggested the gross structure 1 depicted for this compound. The HMBC correlations of other
proton resonances and COSY correlations further supported this structure (Figure 3.7).
The relative configuration of compound 1 was determined by the 1H NMR coupling
constants and ROESY (Figure 3.9) data. A 3J7,8 value of 10.2 Hz suggested that H-7 and H-8
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were trans-diaxially orientated. A 3J10,11 value of 10.2 Hz similarly indicated the trans-diaxial
arrangement of H-10 and H-11. The lack of three-bond coupling of H-11 and H-12 may reflect a
C-11 - C-12 conformation having H-11 and H-12 orthogonally oriented in order to minimize Van
der Waals interaction between the C-10 and C-11 alkyl groups. In the ROESY spectrum H-7
displayed interactions with H-11 and CH3-15 indicating the cofacial orientation of the three
groups. Similarly, H-11 showed interactions with H-7 and CH3-16 (Figures 3.7 & 3.8).
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Table 3.1. NMR Data for Compounds 1-4 in CDCl3- Methanol-d4

Position

1
b

40

2
3
4
5
6
7
8
9

δC
158.0
110.4
161.4
114.2
131.8
81.4
36.8
42.2

10
11
12
13

32.6
89.9
35.6
22.1

14

12.8

15
16
17
1′

17.5
17.5
17.2
133.4

a

δH (J in Hz)

7.69, s
4.72, d (10.2)
1.88, m
1.82, dt (13.2,
3.6)
1.12, q (12.6)
1.76, m
3.07, d (10.2)
1.66, m
1.02, m
1.56, m
0.90, t (7.2)
0.73, d (6.6)
0.84, d (6.6)
0.98, d (6.6)

2
b

δC
158.0
111.8
161.8
114.3
132.9
81.3
36.9
42.2

δC
158.0
111.7
161.8
114.4
7.43, s
133.0
4.73, d (10.2)
81.4
1.87, m
36.8
1.83, dt (13.2, 3.6) 42.1
1.14, q (12.6)

δHa

32.6
89.9
35.6
22.1

1.75, m
3.07, d (10.2)
1.65, m
1.00, m
1.54, m
0.88, t (7.2)

1.76, m
3.08, d (9.6)
1.96, m
1.23, m
1.74, m
3.56, brq (9.0)
3.71, m
0.86, d (6.6)
0.84, d (6.6)
0.97, d (7.2)

12.8

in Hz)

17.8 0.88, d (6.6)
17.5 0.83, d (6.6)
17.1 0.96, d (6.6)
133.4
40

b

3
(J in Hz)

δHa (J

32.6
89.8
30.1
32.3
61.0
17.7
17.6
17.4
133.3

7.42, s
4.72, d (10.2)
1.88, m
1.82, dt (13.2, 3.6)
1.13, q (12.6)

b

4
(J in Hz)

δC
158.0
111.7
161.7
114.3
133.4
81.5
36.8
42.0

δHa

32.7
89.6
30.4
28.4

1.71, m
3.10, d (10.2)
1.61, m
1.21, m
1.61, m
4.02, m
4.13, m
0.88, d (6.6)
0.85, d (6.6)
1.00, d (6.6)

63.0
17.8
17.3
17.6
133.0

7.44, s
4.75, d (10.2)
1.88, m
1.85
1.13, q (12.6)

2′,6′
3′,5′
4′
OH
OCH3
COCH3
COCH3
a1

129.3
128.6
127.9

7.49, d (7.8)
7.43, t (7.8)
7.35, t (7.2)
9.72, s

129.2 7.45, d (7.2)
128.6 7.40, t (7.8)
127.8 7.33, t (7.8)
9.69, s
65.0 4.01, s

129.2 7.42, d (7.8)
128.5 7.38, t (7.8)
127.8 7.13, t (7.8)
9.66, s
65.0 4.03, s

H NMR spectra recorded at 600 MHz. b13C NMR spectra recorded at 100 MHz.
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129.3 7.45, d (7.2)
128.6 7.40, t (7.2)
128.0 7.34, t (7.2)
9.49, s
65.1 4.05
21.1 2.01, s
171.8

Figure 3.1. 1H NMR spectrum of 1

Figure 3.2. Expansion of 1H NMR spectra of 1
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Figure 3.3. COSY spectrum of 1

Figure 3.4. 13C NMR spectrum of 1
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Figure 3.5. DEPT spectrum of 1

Figure 3.6. HMBC spectrum of 1
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Key COSY (

) correlations

Key HMBC (

) correlations

Key ROESY (

) correlations

Figure 3.7. COSY, HMBC, and ROESY correlations of 1
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Figure 3.8. ROESY spectrum of 1

This compound afforded crystals that were suitable for crystallographic analysis. On the
basis of Cu K X-ray diffraction data, the absolute configuration of compound 1 was assigned as
7R, 8R, 10S, 11R, and 12R. The solid-state structure contains four independent molecules, one of
which is illustrated in Figure 3.9. All four have an intramolecular OH...O hydrogen bond to the
tetrahydropyran oxygen, with O...O distances in the range 2.5771(19) to 2.5930 (19) Å. The four
molecules differ only slightly in conformation, except for that about the bond joining the
heterocyclic and phenyl rings, for which C-C-C-C torsion angles vary from -50.5(3)º to +44.(3)º.

46

Figure 3.9. Single-crystal X-ray structure of 1, showing the absolute
configuration of one of the four independent molecules

Compound 2 had a molecular formula of C23H31NO4 as determined by HRESIMS. The 1H
(Figure 3.10) and 13C NMR (Figure 3.11) spectra were similar to those of compound 1 except for
the presence of an O-methyl resonance in the spectra of the former. This indicated that
compound 2 was an O-methyl analogue of compound 1. The COSY (Figure 3.12), HMQC
(Figure 3.13) and HMBC spectra (Figure 3.14) of compound 2 showed correlations identical to
those observed for compound 1. Additionally, the O-methyl resonance showed no cross peaks in
the HMBC spectrum whereas the OH proton (δH 9.69) correlated with C-3 (δC 118.8), C-4 (δC
161.8) and C-5 (δC 114.2) suggesting that the O-methyl group was located on the nitrogen. The
up-field shift of H-6 of compound 2 relative to that of compound 1 is consistent with the
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structural modification. Identical coupling constants and ROESY correlations indicated that
compounds 1 and 2 have the same relative configuration.

Figure 3.10. 1H NMR spectrum of 2

Figure 3.11. 13C NMR spectrum of 2
48

Figure 3.12. COSY spectrum of 2

Figure 3.13. HMQC spectrum of 2
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Figure 3.14. HMBC spectrum of 3

The molecular formula of compound 3 was established as C23H31NO5 by HRESIMS. Its
1

H-NMR spectrum (Figure 3.15) was similar to compound 2, the major differences being the

replacement of the methyl triplet by two diastereotopic oxymethylene hydrogens in the spectrum
of 3. This suggested that compound 3 was the C-14 oxygenated analogue of 2. Comparison of
the 13C NMR data (Figure 3.16) of these compounds also confirmed the replacement of a methyl
by an oxymethylene group in 3. The COSY spectrum of compound 3 (Figure 3.17) displayed
cross peaks between the C-14 oxymethylene (δH 3.58, 3.73) and C-13 methylene protons (δH
1.23, 1.75). The COSY correlations for the rest of the hydrogen resonances were identical to
those of compound 2. In the HMBC spectrum (Figure 3.18) the oxymethylene protons showed
cross peaks with C-13 (δC 32.3) and C-12 (δC 30.1). The remaining HMBC correlations were
identical to those observed for compound 2. These observations suggested that compound 3 was
the C-14 hydroxy analogue of 2. ROESY correlations and coupling constants of H-7, H-9, and
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H-11 of compound 3 were identical to those observed for compound 1 indicating that these two
compounds had the same relative configuration.

Figure 3.15. 1H NMR spectrum of 3

Figure 3.16. 13C NMR spectrum of 3
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Figure 3.17. COSY spectrum of 3

Figure 3.18. HMBC spectrum of 3
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The molecular formula of compound 4 was determined by HRESIMS as C25H33NO6. The
1

H (Figure 3.19) and

13

C NMR (Figure 3.20) spectra, COSY (Figure 3.21), and HMBC (Figure

3.22) correlations of this compound were similar to those observed for compound 3. Major
differences involved the presence of an additional methyl singlet (δH 2.01) and two carbon
signals [δC 21.2 (CH3), 171.8 (CO)] in its 1H and 13C NMR spectra, respectively. The down-field
shift of proton signals due to the C-14 oxymethylene group and HMBC correlations between
these protons and the acetyl carbonyl carbon indicated that compound 4 was the 14-O-acetyl
analogue of compound 3.

Figure 3.19. 1H NMR spectrum of 4
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Figure 3.20.

13

C NMR spectrum of 4

Figure 3.21. COSY spectrum of 4
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Figure 3.22. HMBC spectrum of 4

Since the pyridinone analogues 1-4 presumably share a common biosynthetic origin
involving an aromatic amino acid and an activated polyketide,93 analogues 2, 3, and 4 also
possess 7R, 8R, 10S, 11R, 12R absolute configuration. Such an assumption is supported by the
fact that all four compounds are strongly dextrorotatory.
The in vitro antiplasmodial activities of compounds 1-4 are summarized in Table 3.2.
Compound 1 demonstrated strong antiplasmodial activity whereas compounds 2-4 were inactive.
The selectivity index of antiplasmodial activity was calculated based on their cytotoxicity to
mammalian kidney fibroblasts (Vero cells) determined in parallel experiments. Compound 1 was
moderately cytotoxic to Vero cells.
Compound 2 exhibited moderate activity against both methicillin-sensitive and
methicillin-resistant Staphylococcus aureus (Table 3.3). The cytotoxic potential of these
compounds was further evaluated against a panel of solid tumor cell lines (SK-MEL, KB, BT55

549, SK-OV-3) and kidney epithelial cells (LLC-PK11) (Table 3.4). Compound 1 showed
moderate cytotoxicity against all the cell lines while compound 2 was inactive. The presence of
an N-hydroxy group appears to be essential for the activity of these compounds. It is interesting
to note that a free N-hydroxy group was also a prerequisite for the activity of cordypyridones, a
group of 1,4-dihydroxy-2-pyridinone alkaloids, with moderate antiplasmodial activity previously
reported from fungus Cordyceps nipponica.64

3.4. Bioactivity Results

Table 3.2. Antiplasmodial activity of 1-4

Compound

Chloroquine-sensitive

Chloroquine-resistant

Cytotoxicity

(D6)-clone

(W2)-clone

to Vero cells

IC50 (nM)

S.I.

IC50 (nM)

S. I.

IC50 (nM)

1

0.07

5.0

0.07

5.4

0.38

2

NA

NA

NC

3

NA

NA

NC

4

NA

NA

NC

chloroquinea 0.03

0.31

NC

artemisinina

0.01

NC

0.02

56

a

Positive controls

NC: not cytotoxic
NA: not active
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity

Table 3.3. Antifungal and antibacterial activity of 1-2.

Candida

Aspergillus

Staphylococcus

albicans

fumigatus

aureus

IC50

MIC

IC50

MIC

IC50

MIC

IC50

MIC

1

32.5

NT

23.5

NT

NA

NA

NA

NA

2

NA

NA

NA

NA

7.24

12.98

7.76

12.98

amphotericin B

0.45

2.70

1.16

12.6

NT

NT

NT

NT

ciprofloxacin

NT

NT

NT

NT

0.27

0.75

0.15

0.75

Compound

MRSA

IC50 and MIC (minimum inhibitory concentration, the lowest test concentration that allows no
growth) values are in µM.
NA: not active.
NT: not tested.
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Table 3.4. Cytotoxic activity [IC50 (µM)] of compounds 1-2

Compound

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

Vero

1

4.04

13.46

4.45

7.0

4.4

3.77

2

NA

NA

NA

NA

NA

NA

2.48

1.47

2.2

1.1

>0.9

doxorubicina 11.03

NA: not active.
a

Positive control

3.5. Experimental
3.5.1. General

Melting points were measured with a Uni-melt, Thomas Hoover capillary melting point
apparatus. Optical rotations were measured using a Rudolph Research Analytical Autopol IV
automatic polarimeter model 589-546. UV and IR spectra were recorded on a Varian-50 Bio UV
visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer, respectively.
NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova-600
spectrometer using CDCl3/methanol-d4 as the solvent unless otherwise stated. MS analyses were
performed on an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies,
Palo Alto, CA, USA). Column chromatography was carried out on Merck silica gel 60 (230-400
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mesh). Preparative TLC was carried out using silica gel GF plates (20 X 20 cm, thickness 0.25
mm).
3.5.2. Fermentation, Extraction, and Isolation

Septoria pistaciarum Caracc. (ATCC 22201) was obtained from the American Type
Culture Collection, Manassas, VA and grown in potato dextrose agar plates at 27 ºC for 12 days.
An Erlenmeyer flask containing 100 mL of potato dextrose broth was inoculated with small agar
pieces (0.25 in × 0.25 in) and were incubated at 27 ºC for 7 days on a shaker (RPM = 100). This
seed culture was used to inoculate 20 × 1L Erlenmeyer flasks each containing 500 mL of M-2
medium, (modified Czapex Dox medium : Czapex Dox 35.0 g, yeast extract 1.5 g, malt extract
1.5 g in 1L of distilled H2O) and were incubated at 27 ºC for 28 days on a shaker (RPM = 100).
The culture broth and mycelia were extracted with EtOAc (×3) and the organic layer was
evaporated under reduced pressure to give an oily residue (5.2 g).
The oily extract (5.0 g) was chromatographed over Sephadex LH -20 and eluted with
CHCl3/MeOH (20:80) to give 12 fractions. Fractions 3, 4, 5, 6, and 7 showed antiplasmodial
activity (IC50 < 529 ng/mL). Fractions 3, 4, and 5 were combined and chromatographed over a
reversed phase C18 column eluting with a gradient 10% to 100% MeOH / H2O to yield five
fractions. Subfraction 4 was further purified by crystallization from MeOH and CH2Cl2 to give
compound 1 as white crystals (53.0 mg). Combined fractions 6 and 7 were chromatographed
over a silica gel column using CH2Cl2/hexanes as the eluent to give 10 subfractions. Subfraction
7 was further purified by Sephadex LH-20 (MeOH) followed by preparative TLC (2% MeOH in
CH2Cl2) to give compound 2 (20.0 mg) and compound 3 (12.0 mg).
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Subfraction 4 was

chromatographed over reversed phase C18 eluting with CH3CN / H2O (40:60) to give compound
4 (3.0 mg).
Compound 1: white crystals (CH2Cl2/MeOH); mp 220 0C; [α]26D +201 (c, 0.4, CH3OH);
UV (MeOH) λmax (log ε) 207.1 (3.78), 241.0 (3.75), 296.0 (3.03) nm; IR (CHCl3 ) max 3109,
2963, 2927, 1642, 1556, 1454, 1225 cm-1; 1H and 13C NMR data (see Tables 1 and 2);
HRESIMS [M - H]- m/z 370.2012 (calcd for (C22H29NO4 - H)-, 370.2018 ).
Compound 2: amorphous; [α]26D +15 (c, 0.375, MeOH); UV (MeOH) λmax (log ε) 207.1
(2.15), 241.0 (1.96), 297.0 (0.88) nm; IR (CHCl3 ) max 3318, 2917, 1686, 1047 cm-1;

1

H and

13

C NMR data (see Tables 1 and 2); HRESIMS [M + H]+ m/z 386.2423 (calcd for (C23H31NO4 +

H) +, 386.2331).
Compound 3: amorphous; [α]26D +190 (c, 0.6, MeOH); UV (MeOH) λmax (log ε) 205.0
(3.61), 241.0 (3.46), 290.0 (2.72) nm; IR (CHCl3 ) max 3212, 2929, 2341, 1647, 1557, 1456,
1057 cm-1; 1H and 13C NMR data (see Tables 1 and 2); HRESIMS [M + H]+ m/z 402.236 (calcd
for (C23H31NO5+H)+, 402.228) .
Compound 4: amorphous: [α]26D +47 (c, 0.25, MeOH); UV (MeOH) λmax (log ε) 205.0
(2.56), 241.0 (2.69) nm; IR (CHCl3 ) max 3331, 2925, 2853, 1736, 1647, 1227, 1053 cm-1;
and

13

1

H

C NMR data (see Tables 1 and 2); HRESIMS [M + Na] + m/z 466.2307 (calcd for

(C25H33NO6 + Na)+, 466.2205).
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3.5.3. Crystallographic Data for Compound 1

X-ray data were collected at low-temperature (90 K) on a Bruker Kappa Apex-II diffractometer
equipped with graphite-monochromated CuK ( = 1.54178 Å) source, yielding 14,467
independent data to max = 69.0º. Crystals were monoclinic, space group P21, with a =
11.1427(9), b = 13.0004(10), c = 28.073(2) Å,  = 90.430(5)º, Z = 8. Refinement of the model
containing four independent molecules resulted in R = 0.038 for 1015 parameters. Resonant
scattering, principally from the O atoms, resulted in a Flack94 parameter X = 0.01(9) and a
Hooft95 parameter Y = 0.09(5) for 6739 Bijvoet pairs. This corresponds to a probability of 1.000
that the illustrated configuration is correct.

3.5.4. Biological Assay

3.5.4.1. Antimicrobial Assay

All organisms were obtained from the American Type Culture Collection (Manassas,
VA) and include the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei
ATCC 6258, Cryptococcus neoformans ATCC 90113 and Aspergillus fumigatus ATCC 90906
and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant Staphylococcus
aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC
27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing was performed
using a modified version of the CLSI methods72,71 as described by Samoylenko et al.73 The drug
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controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B (ICN
Biomedicals, Ohio) for fungi were included in each assay.

3.5.4.2. Antiplasmodial Assay

In vitro antiplasmodial activity was determined against D6 (chloroquine sensitive) and
W2 (chloroquine resistant) strains of Plasmodium falciparum as described earlier.69

3.5.4.3. Cytotoxicity Assay

In vitro cytotoxicity was determined against a panel of mammalian cells that included
kidney fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral
epidermal carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3)
cells.76 The assay was performed in 96-well tissue culture-treated plates. Cells were seeded to
the wells of 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples at
different concentrations were added and plates were again incubated for 48 h. The number of
viable cells was determined by using Neutral Red dye and IC50 values were obtained from dose
response curves. Doxorubicin was used as a positive control.
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CHAPTER 4: ANTIPROTOZOAL AND ANTIMICROBIAL COMPOUNDS FROM THE
PLANT PATHOGEN SEPTORIA PISTACIARUM

Some of the results presented in this chapter have been published in the following journal.

Kumarihamy, M.; Khan, S. I.; Jacob, M.; Tekwani, B. L.; Duke, S. O.; Ferreira, D.;
Nanayakkara, N. P. D. Antiprotozoal and antimicrobial compounds from the plant pathogen
Septoria pistaciarum, J. Nat. Prod. 2012, 75, 883-889.

4.1. Summary

Four

new

1,4-dihydroxy-5-phenyl-2-pyridinone

alkaloids,

17-hydroxy-N-(O-

methyl)septoriamycin A (1), 17-acetoxy-N-(O-methyl)septoriamycin A (2), 13-(S)-hydroxy-N(O-methyl)septoriamycin A (3) and 13-(R)-hydroxy-N-(O-methyl)septoriamycin A (4), together
with the known compounds (+)-cercosporin (5), (+)-14-O-acetylcercosporin (6), and (+)-di-Oacetylcercosporin (7), lumichrome, and brassicasterol were isolated from an ethyl acetate extract
of a culture medium of Septoria pistaciarum. Methylation of septoriamycin A (8) with
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diazomethane yielded three di-O-methyl analogues, two of which existed as mixtures of
rotamers. We previously reported in vitro antimalarial activity of septoriamycin A. This
compound also exhibited significant activity against Leishmania donovani promastigotes and
amastigotes. Compounds 5-7 showed in vitro activity against L. donovani promastigotes,
chloroquine-sensitive (D6) and -resistant (W2) strains of Plasmodium falciparum, methicillinsensitive

and

methicillin-resistant

strains

of

Staphylococcus

aureus,

Mycobacterium

intracellulare, Candida glabrata, and moderate cytotoxicity against a panel of cell lines.
Compounds 5, 6, and 7 also exhibited moderate phytotoxic activity against both a dicot (lettuce,
Lactuca sativa) and a monocot (bentgrass, Agrostis stolonifera).

4.2. Introduction

Phytotoxins from plant pathogenic fungi may act as inhibitors of plant-like metabolic
pathways in the apicoplast, a chloroplast-like organelle, essential for the survival of plasmodium
species.41 Previously we reported96 the isolation and identification of the 2-pyridinone alkaloid,
septoriamycin A97 (8) and three of its derivatives from the causative agent of septoria leaf spot
disease in pistachio, Septoria pistaciarum (Ascomycetes), as part of our program to identify
antimalarial compounds from plant pathogenic fungi. Although we detected several minor
alkaloids of the same class in the original extract, their structural elucidation was not possible
due to insufficient quantities. In order to isolate the minor compounds, we recultured the same
fungus under the identical conditions at a larger scale. In the ethyl acetate extract of this
fermentation culture broth, a series of pigments with 2-pyridinone alkaloidal architecture were
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detected. The extract showed herbicidal, antimicrobial, antiplasmodial, and antileishmanial
activities albeit with low selectivity indices. From this extract, four more new minor
septoriamycin A analogues, 17-hydroxy-N-(O-methyl)septoriamycin A (1), 17-acetoxy-N-(Omethyl)septoriamycin A (2), 13-(S)-hydroxy-N-(O-methyl)septoriamycin A (3), and 13-(R)hydroxy-N-(O-methyl)septoriamycin A (4), in addition to the parent and its previously reported
analogues were identified. Septoriamycin A (8), the major 2-pyridinone alkaloid in this extract
showed significant antileishmanial activity in addition to its reported antiplasmodial activity. The
pigments were identified as three known perylenequinones, (+)-cercosporin (5),98 (+)-14-Oacetylcercosporin (6),98 and (+)-di-O-acetylcercosporin (7).99 These pigments have previously
been identified as phytotoxins produced by a number of phytopathogenic Cercospora species
and have been linked to their pathogenicity.100 Their biosynthesis appeared to be controlled by
numerous environmental and physiological factors and the presence of even small amounts of
certain compounds in the medium was found to have a strong stimulatory or inhibitory effect on
their production.100, 101 Their ability to generate reactive oxygen species in the presence of light
has been attributed to their phytotoxic activity.100 Cercosporin and its esters have also been
reported to have antibacterial and antifungal102 activities as well as growth inhibitory effects on
lettuce98 and tomato seeds.102 In this study, the perylenequinones showed antileishmanial,
antiplasmodial, and cytotoxic activities in addition to antibacterial and antifungal activities. Two
more known compounds, lumichrome (11),103 and brassicasterol (12)104 were also isolated and
identified.
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4.3. Results and Discussion

Fractionation of an EtOAc extract of a culture medium of S. pistaciarum by Sephadex
LH-20 gel column chromatography followed by purification using silica gel and RP C 18
chromatography afforded four minor 2-pyridinone alkaloids 1-4 in addition to the known
septoriamycin A (8) and its three derivatives,96 three known perylenequinones (+)-cercosporin
(5), (+)-14-O-acetylcercosporin (6), (+)-di-O-acetyl-cercosporin (7), lumichrome (11), and
brassicasterol (12).
The molecular formula of compound 1 was determined as C23H31NO5 by HRESIMS. UV
maxima (205.0, 240.9, and 297.0 nm) and IR absorptions (3400, 3207, 1647, and 1555 cm-1) of 1
were consistent with those of a 2-pyridinone moiety.96 The aromatic regions of the 1H NMR
(Figure 4.2) and COSY (Figure 4.3) spectra were similar to those observed for 5-phenyl-2pyridinones previously isolated from this species, and consisted of a one-proton singlet and an
A2B2C spin system due to a monosubstituted phenyl group.96 The aliphatic region exhibited two
oxymethine and two methyl doublets indicating the presence of a 2,4-dimethyltetrahydropyran
moiety and an N-methoxy group (Figure 4.3).
HMBC (Figure 4.4) correlations of H-2′ and H-6′ (H7.43) with C-3′ and C-5′
(C128.6), C-4′ (C127.8), C-1′ (C133.3), and C-5 (C114.5), and H-6 (H7.44) with C-2
(C158.0), C-4 (C161.9), C-5 (C114.5), and C-1′ (C133.3) supported the partial structure of
the substituted pyridinone ring moiety. HMBC correlations of the H-7 oxymethine doublet (H
4.73) with C-4 (C161.9), C-2 (C158.0), C-3 (C111.6), C-11 (C86.3), C-9 (C36.4), C-8
(C39.8), and C-15 (C17.8) supported the partial structure of the tetrahydropyran moiety. The
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major difference in the rest of the 1H NMR resonances of compound 1 and the reported96 N-(Omethyl)septoriamycin A (9) is the replacement of the methyl doublet in the chain attached to C11 of the tetrahydropyran ring by two diastereotopic oxymethylene hydrogens. This indicated
that compound 1 was the C-17 oxygenated analogue of 9. The COSY spectrum of compound 1
displayed cross peaks between the C-17 oxymethylene (H 3.60, 3.49) and C-12 methine proton
(H1.87). In the HMBC spectrum the oxymethylene protons showed cross peaks with C-11 (C
86.3), C-12 (C 36.5), and C-13 (C 22.3), and the H-11 oxymethine doublet at 3.36 with C-7
(C81.2), C-9 (C36.4), C-12 (C), C-13 (C), C-16 (C), and C-17 (C63.6)
further confirming that compound 1 was 17-hydroxy-N-(O-methyl)septoriamycin A. (Figure 4.1)
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Lumichrome (11)

brassicasterol (12)

Figure 4.1. Structure of compounds 1 - 12

68

Figure 4.2. 1H NMR spectrum of 1

Figure 4.3. COSY spectrum of 1
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Figure 4.4. 13C NMR spectrum of 1

Figure 4.5. HMBC spectrum of 1
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Figure 4.6. ROESY spectrum of 1

The HRESIMS data established the molecular formula of compound 2 as C25H33NO6.
The 1H (Figure 4.7) and 13C NMR spectra (Figure 4.8) were similar to those of 1 except for the
presence of additional resonances [( 2.06) C 21.1 (CH3), C 171.2 (CO)] originating from an
O-acetyl group. HMBC (Figure 4.9) correlations between the C-12 oxymethylene group and the
acetyl carbonyl carbon indicated that compound 2 was 17-O-acetyl-N-(O-methyl)septoriamycin
A. The remaining HMBC and COSY (Figure 4.10) correlations were identical to those of
compound 1. Both 3J7,8 and 3J10,11 values were 10.2 Hz indicating that these protons are trans –
diaxially oriented. ROESY correlations of compound 1 (Figures 4.6 & 4.11) and 2 were identical
to those observed for septoriamycin A (8) suggesting that these two compounds had the same
relative configurations. Since we have previously assigned the absolute configuration of
septoriamycin A on the basis of X-ray diffraction data,96 and all these compounds presumably
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share a common biosynthetic origin, compounds 1 and 2 also have 7R, 8R, 10S, 11R, and 12R
absolute configuration. It is further supported by their dextrorotatory specific rotations.

Figure 4.7. 1H NMR spectrum of 2

Figure 4.8. 13C NMR spectrum of 2
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Figure 4.9. HMBC spectrum of 2

Figure 4.10. COSY spectrum of 2
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Key COSY (

) correlations

Key HMBC (

) correlations

Key ROESY (

) correlations

Figure 4.11. COSY, HMBC, and ROESY correlations of 1.
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The HRESIMS data of 3 established its molecular formula as C23H31NO5. Comparison of
1

H NMR (Figure 4.12), 13C NMR (Figure 4.13), COSY (Figure 4.14), and HMBC (Figure 4.15)

data of 3 with those of 8 showed that the major difference was the replacement of a methyl triplet
(H) of the latter by a methyl doublet (Hand an oxymethine doublet (
former. These changes could be attributable to the substitution of one of the C-13 diastereotopic
methylene hydrogens in 8 with a hydroxy group indicating that compound 3 is the 13-hydroxy
analogue of N-(O-methyl)septoriamycin A (9). The methyl doublet at H (17-CH3) showed
HMBC cross peaks with C-11 (C), C-12 (C), and C-13 (C) and the oxymethine
multiplet at H with C-11 (C), C-12 (C), and C-17 (C15.9) confirming the C-13
location of the secondary hydroxy group and, thus, compound 3 was 13-hydroxy-N-(Omethyl)septoriamycin A.
ROESY (Figure 4.16) data and 1H NMR coupling constants of compound 3 showed close
correlations to those reported96 for septoriamycin A (8). Our attempts to determine the absolute
configuration at C-13 by Mosher analysis were unsuccessful. Treatment of compound 3 with the
R- and S-Mosher’s acid chlorides afforded a mixture not worth resolving. Methylation prior to
acylation also yielded a mixture of products. The absolute configuration of compound 3 was
proposed by a 3J12, 13 - based comparison of compounds 3 and 4 (Figure 4.17).
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Figure 4.12. 1H NMR spectrum of 3

Figure 4.13. 13C NMR spectrum of 3
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Figure 4.14. COSY spectrum of 3

Figure 4.15. HMBC spectrum of 3
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Figure 4.16. ROESY spectrum of 3
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Figure 4.17. Rotamer representation of 3 and 4
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Compound 4 had the same molecular formula, C23H31NO5, as that of 3 based on
HRESIMS data. The 1H NMR (Figure 4.18) and

13

C NMR (Figure 4.19) spectra of these

compounds were similar except for the down-field shift of the oxymethine proton ( 4.20) and
the up-field shift of a methyl doublet (H 1.00). The COSY (Figure 4.20) and HMBC (Figure
4.21) spectra of 4 showed the same correlations as those observed for 3 suggesting that both
compounds have the same gross structure. Identical coupling constants and ROESY (Figure
4.22) correlations for the protons in the tetrahydropyran moiety indicated that they had the same
relative configuration except at C-13. Since compounds 3, 4, and 8 presumably share a common
biosynthetic origin, compounds 3 and 4 also have 7R, 8R, 10S, 11R, 12R absolute configuration.
As described earlier for compound 3, our attempts to determine the absolute configuration of the
C-13 stereogenic center by Mosher analysis were unsuccessful. Thus, we used a J-based
approach relying on 1H NMR coupling constants combined with ROESY correlations, to assign
the C-13 absolute configuration of compounds 3 and 4. An observed 3J12, 13 value of 7.2 Hz of 3,
suggested a dihedral angle of ca 30o or 150o between H-12 and H-13. Eight rotamers are possible
for 3 with these dihedral angles for the S (3a – 3d) and R (3e -3h) epimers (Figure 4.17).
Observed ROESY correlations between H-12 and H-13, H-13 and CH3-17, and CH3-14 – CH317 ruled out all conformers except 3a as the probable most abundant rotamer for compound 3 in
solution indicating a 13S absolute configuration. Similarly, an observed 3J12, 13 of 1.0 Hz for 4
supported the fact that the dihedral angle between H-12 and H-13 was 900 as shown in Figure
4.17 for the 13R (4a - 4b) and S (4c – 4d) epimers. In the ROESY spectrum, H-12 showed
correlation with H-13 and CH3-14 and absence of interaction between CH3-14 and CH3 -17
indicating 4a as the dominant rotamer and, hence, 13R as absolute configuration.
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Figure 4.18. 1H NMR spectrum of 4

Figure 4.19. 13C NMR spectrum of 4
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Figure 4.20. COSY spectrum of 4

Figure 4.21. HMBC spectrum of 4
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Figure 4.22. ROESY spectrum of 4

Methylation of compounds 3 and 4 with diazomethane afforded several products.
Treatment of septoriamycin A (8) with diazomethane as a model gave three products, whereas
methylation with MeI and Cs2CO3 afforded a single compound which was identified as analogue
9. The products of diazomethane methylation of septoriamycin A were separated by
chromatography. All these products had the same molecular formula, C24H33NO4, by HRESIMS,
suggesting that they were di-O-methyl derivatives. The 1H NMR (Figure 4.23) spectrum of the
least polar compound (10a) was similar to that of 9 except for the presence of an additional Omethyl resonance in the former. The 13C NMR (Figure 4.24) spectrum of this compound showed
changes in resonances in the pyridone ring. A down-field shift of C-4 (C indicated that the
carbonyl group now resided at this carbon suggesting 10a was N,2-di-O-methylseptoriamycin A.
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A hypsochromic shift of the UV absorption (max 278.9 nm) when compared to 9 (max 295
nm)105 and COSY and HMBC correlations further supported this structure.

Figure 4.23. 1H NMR spectrum of 10a

Figure 4.24. 13C NMR spectrum of 10a
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Table 4.1. 1H, and 13C, NMR data for compounds 1-4 in CDCl3/Methanol-d4.

1
position

δHa (J in Hz)

2
δCb

δHa (J in Hz)

3
δCb

δHa (J in Hz)

4
δCb

δHa (J in Hz)

δCb

2

158.0

158.0

158.0

158.2

3

111.6

111.4

112.0

112.0

4

161.9

161.8

161.6

161.7

5

114.5

114.3

114.5

114.8
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6

7.43, s

133.0

7.44, s

133.1

7.42, s

132.9

7.43, s

132.8

7

4.73, d (10.2)

81.2

4.74, d (10.2)

81.3

4.70, d (10.2)

80.8

4.66, d (10.2)

80.9

8

1.87, m

39.8

1.91, m

36.4

1.91, m

36.2

1.91, m

36.7

9

1.34, q (12.6)

36.4

1.30, q (12.6)

36.5

1.06, q (12.6)

42.6

1.16, q (12.0)

42.2

1.98, brd (13.2)

2.00, (overlap)

1.80, dt (13.8, 3.6)

1.84, dt (13.2, 3.6)

10

1.69, m

35.8

1.64, m

36.0

2.03, m

34.1

1.89, m

32.9

11

3.36, d (10.2)

86.3

3.33, d (10.2)

86.2

3.14, d (10.2)

88.9

3.12, dd (10.2, 2.8)

88.5

12

1.87, m

36.5

2.00, m

37.0

2.05, m

41.4

1.75, m

38.7

13

1.02, m, 1.58, m

22.3

1.02, m, 1.55, m

22.3

3.78, m (7.2, 7.2)

68.9

4.20, m (6.6, 1.0)

66.0

14

0.88, t (7.2)

12.6

0.89, t (7.2)

12.6

1.16, d (6.6)

23.1

1.16, d (6.3)

22.8

15

0.91, d (6.6)

17.8

0.91, d (7.2)

17.7

0.85, d (6.6)

17.9

0.87, d (6.6)

17.9
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16

0.95, d (6.6)

17.1

0.97, d (7.2)

17.0

0.83, d (6.6)

17.7

0.84, d (6.6)

17.7

17

3.49, dd (10.6, 3.6)

63.6

3.91, dd (11.2, 5.4)

65.3

0.93, d (7.2)

15.9

1.01, d (7.2)

10.5

3.60, dd (10.6, 3.6)
1′

3.98, dd (11.6, 4.5)
133.3

133.4

133.4

133.7

2′, 6′

7.44, d (7.3)

129.2

7.44, d (7.3)

129.3

7.43, d (7.3)

129.2

7.43, d (7.3)

129.4

3′, 5′

7.39, t (7.2)

128.6

7.40, t (7.3)

128.6

7.38, t (7.8)

128.5

7.36, d (7.2)

128.6

4′

7.32, t (7.2)

127.8

7.34, t (7.3)

127.9

7.32, t (7.2)

127.7

7.30, t (7.2)

127.8

OH

9.63, s

OCH3

4.04, s
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COCH3
COCH3

a1

9.47, s
65.0

9.63, s

4.06, s

65.0

2.06, s

21.1

4.04, s

171.2

H NMR spectra recorded at 600 MHz, b13C NMR spectra recorded at 100 MHz
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9.65, s
65.0

4.05, s

65.0

Their 1H and 13C NMR spectra were similar to those of compound 9 but had an additional
methoxy resonance. HMBC correlations showed that the additional methoxy group correlated to
C-4 indicating that 10b was N,4-di-(O-methyl)septoriamycin A. At 100 oC in pyridine,
duplicated 1H NMR (Figure 4.27) resonances coalesced but were restored to the original ratio
when the temperature returned to ambient conditions (Figure 4.28). Atropisomers of 3cyclohexyl- or 3-cycloheptyl-N,4-dihydroxy-2-pyridone alkaloids have previously been isolated
from several fungal species.64,

105-108

Even though a number of 3-pyrano-N,4-dihydroxy-2-

pyridone alkaloids similar to septoriamycin A analogues have been identified109 from fungal
sources, none have been reported to exist as rotamers. The introduction of a 4-methoxy group
appears to cause restricted rotation about the C-3-C-7 bond giving rise to rotamers. The most
polar compound (10c) showed ionic characteristics. 1H (Figure 4.29) and 13C NMR (Figure 4.30)
data indicated that the compound also existed as a 3:1 mixture of two diastereomeric rotamers.
HMBC correlations showed that the methoxy resonance correlated to C-2 and C-4 suggesting
that 10c is the 2,4-di-O-methylpyridinone-N-oxide analogue of septoriamycin A. The presence of
the 4-methoxy group appears to cause restricted rotation about the C-3-C-7 bond. At 100 oC in
pyridine duplicated 1H NMR (Figure 4.31) resonances coalesced. Even though the original ratio
of rotamers reappeared at ambient temperature some decomposition of 10c was also observed
(Figure 4.32).
The known perylenequinones, (+)-cercosporin (5),98 (+)-14-O-acetylcercosporin (6),98, 99 and (+)di-O-acetylcercosporin (7),99 lumichrome (11),103 and brassicasterol (12),104 were identified by
comparing their spectroscopic data with literature data. The absolute configurations of 5-7 were
determined by comparing experimental and reported electronic circular dichroism data.110,
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The helicity of compounds 5-7 was confirmed as M (aS) and the absolute configuration of both
C-14 and C-17 as R.112

Figure 4.25. 1H NMR spectrum of 10b

Figure 4.26.

13

C NMR spectrum of 10b
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Figure 4.27. 1H NMR spectrum of 10b (at 100 oC in pyridine)

Figure 4.28. 1H NMR spectrum of 10b (at 25 oC in pyridine)
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Figure 4.29. 1H NMR spectrum of 10c

Figure 4.30. 13C NMR spectrum of 10c
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Figure 4.31. 1H NMR spectrum of 10c (at 100 oC in pyridine)

Figure 4.32. 1H NMR spectrum of 10c (at 25 oC in pyridine)
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Table 4.2. 1H and 13C NMR data (methylated compounds 10a, 10b, and 10c) in CDCl3/Methanol-d4.

position

10a
δHa (J in Hz)

10b
δCb

10c

δHa (J in Hz)

δCb

δHa (J in Hz)

δCb

2

155.0

159.2

157.2

158.0

156.0

3

119.5

124.3

122.8

125.6

125.3

4

177.0

164.9

164.8

155.7

157.0

5

134.6

117.2

115.9

128.5

128.5
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3

6

7.51, s

132.7

7.44, s

7.49, s

133.4

134.0

8.15, s

8.14, s

139.6

139.7

7

4.63, d (10.2)

78.4

4.56, d (10.2)

4.21, d (10.2)

79.4

79.5

4.33, d (10.4)

4.33, d (10.4)

79.4

80.7

8

2.0, m

36.3

2.3, m

2.3, m

33.8

33.8

2.44, m

2.52, m

32.6

32.9

9

1.78, m

43.4

1.79, m

1.84, m

43.2

43.1

1.86, m

1.86, m

43.1

43.1

1.04, m

1.06, m

0.96, m

0.96, m

1.02, m
10

1.69, m

33.7

1.72, m

1.72, m

32.3

31.9

1.88, m

1.88, m

32.4

32.5

11

2.92, d (12.0)

89.2

2.97, d (12.0)

2.87, d (12.0)

89.0

88.9

2.92, d (10.0)

2.94, d (10.0)

89.8

90.0

12

1.54, m

34.2

1.57, m

1.57, m

36.1

36.7

1.60, m

1.60, m

36.0

36.0

13

1.54, m

22.8

1.53, m

1.53, m

22.6

21.9

1.5, m

1.5, m

22.5

22.5

0.85, m

0.85, m

1.1, m

1.1, m

0.82, m
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14

0.84, t (7.2)

13.0

0.84, t (6.6)

0.84, t (6.6)

12.7

12.4

0.87, t (6.6)

0.87, t (6.6)

12.9

12.8

15

0.68, d (6.6)

17.6

0.80, d (6.6)

0.80, d (6.6)

17.5

17.8

0.81, d (6.6)

0.81, d (6.6)

17.6

17.6

16

0.77, d (6.6)

17.7

0.75, d (6.6)

0.68, d (6.6)

17.3

17.6

0.64, d (6.4)

0.67, d (6.6)

17.7

17.8

17

0.89, d (6.6)

17.0

0.91, d (6.6)

0.91, d (6.6)

16.8

17.0

0.90, d (6.6)

0.90, d (6.6)

17.2

17.2

133.8

133.8

133.0

133.0

1′

126.6

2′, 6′

7.56, d (7.2)

128.9

7.43, d (7.2)

7.43, d (7.2)

128.6

128.5

7.48, d (6.8)

7.48, d (7.5)

129.0

128.9

3′, 5′

7.33, t (7.2)

128.3

7.39, t (7.2)

7.39, t (7.2)

128.4

128.5

7.42, t (6.8)

7.42, d (7.5)

128.9

128.7

4′

7.25, t (7.2)

127.8

7.34, t (7.2)

7.34, t (7.2)

127.6

127.5

7.39, t (7.3)

7.39, t (7.3)

129.8

129.8

OCH3

4.01, s

66.8

4.08, s

4.08, s

64.5

64.5

3.36, s

3.37, s

61.7

62.1

OCH3

4.0, s

64.4

4.01, s

3.34, s

61.5

61.2

4.16, s

4.14, s

60.6

60.4
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a1

H NMR spectra recorded at 600 MHz, b13C NMR spectra recorded at 100 MHz
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Compounds 1-4 showed no antimicrobial, antifungal, antiprotozoal, phytotoxic, or
cytotoxic activity in vitro. Compounds 5-7 showed moderate in vitro antiplasmodial activity
(Table 4.3) but were cytotoxic to Vero cells. Their low selectivity indices (ratio of cytotoxicity
vs. antiplasmodium activity) preclude them as antimalarial drug leads. Even though the plant
pathogen S. pistaciarum is host-specific to pistachio, compounds 5-7 showed nonspecific
moderate phytotoxic activity towards both bentgrass (A. stolonifera) and lettuce (L. sativa cv. L.,
Iceberg) in the presence of light (Table 4.4). General phytotoxicity of phytotoxins from hostspecific pathogens is very common. The biosynthesis of cercosporin (5) appeared to be
controlled by numerous environmental and physiological factors and their production has been
linked to the pathogenicity of fungi.100, 101 The possible mechanism of phytotoxic activity of this
type of compounds has previously been attributed to their ability to generate reactive oxygen
species in the presence of light.100 This suggested that the selective inhibition of the plant-like
metabolic pathways in the apicoplast of the malaria parasite41 is not responsible for the observed
antimalarial activity of compounds 5-7. Compounds 5-7 also showed significant antileishmanial
activity with IC50 values of 1.14 M, 1.7 M, and 3.1 M, respectively (Table 4.5). Compound 5
was active against both methicillin-sensitive and methicillin-resistant Staph. aureus with IC50
values of 2.2 and 2.3 M, respectively, and MIC values in the range of 4.7 – 9.4 µM (Table 4.6).
This compound also showed weak activity against M. intracellulare. Compounds 6 and 7
exhibited weak activity against C. glabrata, M. intracellulare, and methicillin-sensitive and
methicillin-resistant Staph. aureus.
Septoriamycin A (8), which demonstrated good antiplasmodial and antifungal activities,96
exhibited significant antileishmanial activity against Leishmania donovani promastigotes with an
IC50 of 0.11 M and an IC90 of 0.29 M (Table 4.5) and was more potent than the positive
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controls pentamidine and amphotericin B. It also showed good activity against Leishmania
donovani amastigotes with no toxicity to macrophages (Table 4.5).
The cytotoxic potential of compounds 5-7 was further evaluated against a panel of human
solid tumor cell lines (SK-MEL, KB, BT-549, and SK-OV-3) and pig kidney epithelial cells
(LLC-PK11) (Table 4.7). Moderate cytotoxicity was observed against all the cell lines. The di-Omethyl derivatives of septoriamycin A, 10a, 10b and 10c were also evaluated and compound 10c
exhibited weak antibacterial and antiplasmodial activities whereas 10a and 10b were inactive in
these assays.
Structural features suggest that septoriamycin A may act as a hydroxamic acid analogue.
Hydroxamic acid derivatives are also known25, 113 to target histone deacetylase of the parasites
which cause malaria, schistosomiasis, trypanosomiasis, toxoplasmosis, and leishmaniasis. The
apicoplast of the malaria parasite also possesses a family of class II histone deacetylase (HDAC)
proteins which are also present in other photosynthetic eukaryotes and primitive algae.22 This
unusual enzyme (CpHDAC3) catalyzes the deacetylation of histone tails to promote epigenetic
regulation and some cellular processes of the parasite.22,

23

A number of hydroxamic acid

analogues which inhibit histone deacetylase have been synthesized and their in vitro
antiplasmodial and in vivo antimalarial activities have been evaluated.114,

115

Some of these

compounds have shown selective potent in vitro activity but low in vivo activity in a mouse and
a monkey model due to metabolic instability.115 Human and mouse liver microsomes rapidly
converted the linear hydroxamic acids test compounds to carboxylic acids rendering them
inactive.115 Septoriamycin A (8), a cyclic hydroxamic acid was evaluated in a P. bergheiinfected mouse model. At a dose of 100 mg/kg, the compound showed no toxicity and no
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antimalarial activity (Table 4.8). This compound was also submitted for in vivo antileishmanial
activity in a mouse model. The results have not yet been received.

4.4. Bioactivity Results

Table 4.3. Antiplasmodial activity of 5-7 and 10c

Compound

a

Chloroquine-sensitive

Chloroquine-resistant

Cytotoxicity

(D6)-clone

(W2)-clone

to Vero cells

IC50 nM

S.I.

IC50 nM

S. I.

IC50 nM

5

1.08

4.8

1.62

3.2

5.24

6

2.78

1.9

3.12

1.7

5.21

7

2.75

1.6

1.94

2.3

4.53

10c

6.76

>1.1

6.51

>1.2

NC

chloroquinea

0.03

0.31

NC

artemisinina

0.02

0.01

NC

Positive controls

NC not cytotoxic
S. I. (selectivity index) = IC50 for cytotoxicity /IC50 for antiplasmodial activity
IC50: concentration causing 50% growth inhibition
IC90: concentration causing 90% growth inhibition
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Table 4.4. Phytotoxic activity of 5-7

Compound

Concentration (mM)

Lettuce

Bentgrass

5

1.87

3

2

6

1.73

2

4

7

1.62

3

4

Ranking based on scale of 0 to 5
0 = no effect
5 = no growth

Table 4.5. Antileishmanial activity of 5-8 in µM

L.donovani

Macrophage

Cytotoxicity

promastigotes

amastigotes

(Transformed THP1 cells)
Selectivit

Compound

IC50

IC90

IC50

IC90

IC50

IC90

y

5

1.14

2.81

NT

NT

NT

NT

NT

6

1.7

8.5

NT

NT

NT

NT

NT

7

3.1

9.7

NT

NT

NT

NT

NT

8

0.11

0.29

1.18

1.48

>26.9

>26.9

22.79

pentamidinea

2.9

5.58

8.72

20.18

>58.75

>58.75

6.73

amphotericin Ba

0.18

0.38

0.15

1.88

3.62

8.72

24.13
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a

Positive controls

IC50 concentration causing 50% growth inhibition
IC90 concentration causing 90% growth inhibition
Selectivity = IC50 for cytotoxicity /IC50 for macrophage amastigotes activity
NT = Not tested

Table 4.6: Antifungal and antibacterial activity of 5 -7 and 10c

Candida

Staphylococcus MRSA

Mycobacterium

glabrata

aureus

intracellulare

IC50

MIC

IC50

MIC

IC50

MIC

IC50

5

NA

NA

2.2

4.7

2.3

9.4

3.5

NA

6

4.1

NA

6.9

17.3

5.9

34.7

7.1

NA

7

7.9

NA

20.0

NA

26.4

NA

8.7

NA

10c

NA

NA

23.1

NT

26.8

NT

NA

NA

amphotericin Ba

0.45

2.70

NT

NT

NT

NT

NT

NT

ciprofloxacina

NT

NT

0.27

1.17

0.27

1.11

0.72

1.5

Compound

a

MIC

Positive controls

IC50 and MIC (concentration causing 50% growth inhibition and the lowest test concentration
that allows no growth) values are in 
NA: not active
NT: not tested
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Table 4.7. Cytotoxic activity [IC50 ()] of 5-7
Compound

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

5

3.6

7.1

10.8

3.7

3.9

6

3.8

8.5

8.6

4.0

10.1

7

4.9

8.7

8.7

4.8

9.4

doxorubicina

1.6

2.6

2.6

1.5

1.6

SK-MEL = human malignant melanoma
KB = human epidermal carcinoma
BT-549 = human breast carcinoma (ductal)
SK-OV-3 = human ovary carcinoma
LLC-PK11 = pig kidney epithelial

Table 4.8. In vivo antimalarial activity of 8

Survival2

Day of

MST3 Cure4

Treatment

Dose

% Parasitemia

(PO)

(mg/kg × #

suppression1

days post

Day 5

Day 7

-

-

0/5

17/19/17/19/17

17.8

0/5

Death

infection)
vehicle

×3

chloroquinea

100 × 3

100

100

5/5

28/28/28/28/28

28

0/5

8

100 × 3

37.18

40.37

0/5

17/17/17/17/12

16

0/5
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1

% Suppression in parasitemia is calculated by considering the mean parasitemia in the vehical

control as 100%.
Parasitemia suppression < 80% is considered as non-significant
2

Number of animals that survived day 28/total animals in group (the day of the death-post

infection)
3

% MST – mean survival time (days)

4

Number of mice without parasitemia (cured) till day 28 post-infection

4.5. Experimental
4.5.1. General

Optical rotations were obtained using a Rudolph Research Analytical Autopol IV
automatic polarimeter model 589-546. Melting points were measured with a Uni-melt, Thomas
Hoover capillary melting point apparatus. UV and IR spectra were determined on a Varian-50
Bio UV visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer,
respectively. NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova600 spectrometer using CDCl3 and methanol-d4 unless otherwise stated. MS data were obtained
from an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto,
CA, USA). Column chromatography and preparative TLC were carried out using Merck silica
gel 60 (230-400 mesh) and silica gel GF plates (20 x 20 cm, thickness 0.25 mm), respectively.
HPLC analysis was conducted on an Hewlett-Packard Agilent 1100 with diode array detector.
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4.5.2. Fermentation, Extraction, and Isolation

The plant pathogenic fungus, Septoria pistaciarum Caracc. (ATCC 22201) was obtained
from the American Type Culture Collection, Manassas, VA and it was grown as previously
reported.2
The oily extract (3.3 g) was chromatographed over Sephadex LH -20 and eluted with
80% MeOH in CHCl3 to give 16 fractions. Fractions 2 -11 which showed antiplasmodial activity
and were combined and chromatographed over a reversed phase C18 column eluting with a
gradient of 10 to 100% MeOH-H2O to yield eight fractions. Subfractions 2, 3, and 4 were
combined and separated on Sephadex LH-20 (MeOH) to give compounds 1 (5.0 mg) and 8 (35
mg). Subfraction 5 was chromatographed over a silica gel column using CH2Cl2-hexanes as the
eluent to give compound 2 (8.0 mg). Combined fractions 6, 7, and 8 were chromatographed over
a silica gel column using CH2Cl2-hexanes as the eluent to give 10 subfractions. Subfraction 2, 3,
and 5 were combined and further separated using a C18 reversed phase HPLC column eluting
with MeCN:H2O, (1:1), flow rate 3.5 mL/min, to give compounds 3 (3.5 mg) and 4 (8.0 mg).
Subfractions 6, 7, and 8 were combined and purified on Sephadex LH-20 (MeOH) to give
compounds 5 (14.0 mg), 6 (12.0 mg), and lumichrome (3.0 mg). Subfractions 9 and 10 were
combined and chromatographed over a silica gel column using CH2Cl2-hexanes as the eluent to
give compound 7 (10.0 mg) and brassicasterol (8.0 mg).

Compound 1: amorphous powder: []26D +112 (c 0.05, MeOH); UV (MeOH); λmax (log
ε) 205.0 (3.56), 240.9 (3.51), 297.0 (2.79) nm; IR (CHCl3 ) max 3400, 3207, 2967, 2929, 1647,
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1555, 1454, 1049 cm-1; 1H and 13C NMR data (see Table 1); HRESIMS [M - H]+ m/z 400.2118
(calcd for [C23H31NO5 - H]+, 400.2124) .

Compound 2: amorphous powder: []26D +101 (c 0.05, MeOH); UV (MeOH); UV
(MeOH) λmax (log ε) 204.0 (3.44), 240.0 (3.25), 295.9 (2.56) nm; IR (CHCl3 ) max 3331, 2967,
2925, 1740, 1651, 1230, 1045 cm-1; 1H and

13

C NMR data (see Table 1); HRESIMS [M + H]+

m/z 444.2370 (calcd for [C25H33NO6 + H]+, 444.2386).

Compound 3: amorphous powder: []26D -38 (c 0.43, CH3OH); UV (MeOH); λmax (log ε)
208.2 (3.94), 241.9 (3.92), 297.0 (3.19) nm; IR (CHCl3 ) max 3405, 3201, 2965, 2929, 1644,
1551, 1455, 1219, 755 cm-1; 1H and 13C NMR data (see Table 1); HRESIMS [M + H + Na]+ m/z
425.2172 (calcd for [C23H31NO5 + H + Na ]+, 425.2178).

Compound 4: amorphous powder: []26D +130 (c 0.2, MeOH); UV (MeOH); λmax (log ε)
207.1 (3.01), 241.0 (2.95), 295.1 (2.10) nm; IR (CHCl3 ) max 3422, 3159, 2926, 1641, 1541,
1456 cm-1; 1H and 13C NMR data (see Table 1); HRESIMS [M + H + Na]+ m/z 425.2174 (calcd
for [C23H31NO5 + H + Na ]+, 425.2178).

Methylation of Septoriamycin A (8) with MeI:

A mixture of MeI (4 mL), Cs2CO3 (10.0 mg), and compound 8 (10.0 mg) in acetone was
stirred at room temperature for 5 h. The reaction mixture was filtered, and the solvent was
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evaporated. The product was dissolved in CH2Cl2 and passed through a plug of florisil to give
N-(O-methyl)septoriamycin A (9).

Methylation of Septoriamycin A (8) with Diazomethane:

A solution of 8 (60 mg) in MeOH was treated with excess diazomethane in Et2O at 0 οC
for 2 h. The solvent was evaporated and the mixture was separated by PTLC (40% EtOAc in
hexanes) to yield compounds 10a (8 mg), 10b, and 10c. Compounds 10b and 10c were further
purified by HPLC using a reversed phase Luna C18 column (1 × 25 cm) with MeOH: H2O (92:8)
as the mobile phase at a flow rate of 4 mL/min, to give compounds 10b (5 mg) and 10c (6.0 mg).

Compound 10a: amorphous powder: []26D +14 (c 0.5, MeOH); UV (MeOH); λmax (log
ε) 205.0 (3.75), 232.0 (3.68), 278.9 (3.41) nm; IR (CHCl3 ) max 2959, 2929, 2873, 1627, 1547,
1469, 1046 cm-1; 1H and 13C NMR data (see Table 2); HRESIMS [M + Na]+ m/z 422.2307 (calcd
for [C24H33NO4 + Na]+, 422.2307).

Compound 10b: amorphous powder: UV (MeOH) λmax (log ε) 204.0 (3.39), 235.0 (3.18),
308.0 (2.65) nm; IR (CHCl3) max 2958, 2929, 1740, 1656, 1524, 1457 cm-1; 1H and

13

C NMR

data (see Table 2); HRESIMS [M +H] + m/z 400.2472 (calcd for [C24H33NO4 + H] +, 400.2487).
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Compound 10c: amorphous powder: UV (MeOH) λmax (log ε) 207.0 (2.58), 240.9 (2.47),
307.1 (1.70) nm; IR (CHCl3) max 2900, 2850, 1575, 1450 cm-1; 1H and 13C NMR data (see Table
2); HRESIMS [M + Na] + m/z 422.2279 (calcd for [C24H33NO4 + Na] +, 422.2307).

Compound 5: Red crystals (MeOH): mp 239 0C (lit.110 240-241.5 0C); UV (MeOH)
λmax (log ε) 210.0 (3.71), 221.0 (3.72), 267.0 ( 3.55) , 470.0 (3.42) , 563.0 (2.98) nm; IR (CHCl3)

max 3396, 2924, 1616, 1267 cm-1 1H and

13

C NMR and CD data were consistent with those

reported.98, 110, 112

Compound 6: Red crystals (MeOH): mp 135 0C (lit.99 134 0C); UV (MeOH) λmax (log ε)
222.0 (3.9), 269.0( 3.74) , 471.0 (3.62) , 563.0 (3.2) nm; IR (CHCl3) max 3338, 1735, 1616, 1266
cm-1 1H and 13C NMR and CD data data were consistent with those reported.98, 99

Compound 7: Red amorphous powder: UV (MeOH) λmax (log ε) 222.0 (3.9), 270.0 (
3.84) , 470.1 (4.0) , 563.3 (3.26) nm; IR (CHCl3) max 2921, 1736, 1617, 1211 cm-1 1H and 13C
NMR and CD data were consistent with those reported.99

4.5.3. Biological Assay

4.5.3.1. Antiplasmodial Assay
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The antiplasmodial activity was determined against D6 (chloroquine sensitive) and W2
(chloroquine resistant) strains of Plasmodium falciparum in an in vitro assay as described
earlier.69 Artemisinin and chloroquine were included as the drug controls and IC50 values were
computed from the dose response curves using Microsoft Excel software.

4.5.3.2. Phytotoxicity Assay

The bioassay for phytotoxicity was carried out according to the procedure described by
Dayan et al.70 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa cv. L., Iceberg),
in 24-well plates.

4.5.3.3. Antileishmanial Assay

The in vitro antileishmanial activity of the compounds was carried out on a culture of
Leishmania donovani promastigotes.74 Pentamidine and amphotericin B were used as standard
antileishmanial agents. The IC50 values for each compound were computed from the growth
inhibition curve using Microsoft Excel software.

4.5.3.4. Macrophage Amastigote Assay

A recently developed promastigote rescue assay by Jain et al. was used.75
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4.5.3.5. Antimicrobial Assay

All organisms were obtained from the American Type Culture Collection (Manassas, VA) and
included the fungi Candida albicans ATCC 90028, Candida glabrata ATCC 90030, Candida
krusei ATCC 6258, Cryptococcus neoformans ATCC 90113, and Aspergillus fumigatus ATCC
90906,

and

the

bacteria

Staphylococcus

aureus

ATCC

29213,

methicillin-resistant

Staphylococcus aureus ATCC 33591 (MRSA), Escherichia coli ATCC 35218, Pseudomonas
aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing
was performed using a modified version of the CLSI methods71,72 as described73 by Samoylenko
et al. The drug controls ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B
(ICN Biomedicals, Ohio) for fungi were included in each assay.

4.5.3.6. Cytotoxicity Assay for Mammalian Cells

In vitro cytotoxicity was determined against a panel of mammalian cells that included kidney
fibroblast (Vero), kidney epithelial (LLC-PK11), malignant melanoma (SK-MEL), oral epidermal
carcinoma (KB), breast ductal carcinoma (BT-549), and ovary carcinoma (SK-OV-3) cells as
described earlier.76 The number of viable cells was determined by using Neutral Red dye and
IC50 values were obtained from dose response curves. Doxorubicin was used as a positive
control.
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4.5.3.7. In Vivo Antimalarial Assay

The in vivo antimalarial activity was determined in mice infected with P. berghei (NK-65
strain), originally obtained from the Walter Read Army Institute of Research, Silver Spring, MD.
Male mice (Swiss Webster strain) weighing 18-20 g were intraperitoneally inoculated with 2 x
107 parasitized red blood cells obtained from a highly infected donor mouse. Mice were divided
into different groups with at least six mice in each group. Compounds stocks were prepared in
DMSO. The mice infected with P. berghei were orally administered 100 μL of the compound.
The animals were closely observed for at least 2 h after every dose for any apparent signs of
toxicity. Blood smears were prepared on different days starting from 5 days post infection
(through 28 days) by clipping the tail end, stained with Giemsa, and the slides were observed
under microscope for determination of parasitemia. Mice without parasitemia through day 28
postinfection were considered cured.
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CHAPTER 5
PART-1: ANTIMALARIAL COMPOUNDS FROM SEPTORIA MUSIVA

5.1.1. Summary

An EtOAc extract of the culture medium of Septoria musiva showed antiplasmodial,
antimicrobial, antileismanial, and phytotoxic activities. Bioassay-guided fractionation of this
extract led to the isolation of septoriamycin A (1) and (+)-cercosporin (2) as the compounds
responsible for antiplasmodial, antimicrobial, and antileishmanial activities. (+)-Cercosporin
showed phytotoxic activity whereas both compounds exhibited moderate cytotoxic activity
against mammalian cell lines.

5.1.2. Introduction

Septoria musiva is the causal agent of stem canker and leaf spot disease leading to
defoliation in Populus sp (poplar tree). Chemical or biological investigation of S. musiva has not
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been reported. An EtOAc extract of the culture medium S. musiva obtained from the American
Type Culture Collection (ATCC 52800) showed antiplasmodial, phytotoxic, antimicrobial, and
antileishmanial activities. This extract also exhibited moderate cytotoxicity towards Vero cells.
Bioassay-guided fractionation of the EtOAc extract led to the isolation of septoriamycin A (1)
and (+)-cercosporin (2) as the active constituents.

5.1.3. Results and Discussion

S. musiva was obtained from the American Type Culture Collection (ATCC 52800) and
grown in potato dextrose agar (PDA) plates. Although the fermentation was carried out in
several culture media such as PDB, Czapex Dox, V-8 (100% vegetable juice), and solid rice,
only Czapex Dox medium afforded an extract with the antiplasmodial activity [720 ng/mL for
chloroquine-sensitive (D6) and 570 ng/mL for chloroquine-resistant (W2) strains].
Chromatographic separation of this extract yielded septoriamycin A (1) and (+)-cercosporin (2)
as the active compounds (Figure 5.1). These compounds showed identical physical,
spectroscopic data, and biological activity profiles with those of the same compounds isolated
from S. pistaciarum.96, 117
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septoriamycin A (1)

(+)-cercosporin (2)

Figure 5.1.1. Structure of compounds 1 and 2

5.1.4. Experimental

5.1.4.1. General

Optical rotations were measured using a Rudolph Research Analytical Autopol IV
automatic polarimeter model 589-546. NMR spectra were recorded on a Varian-Mercury-plus400 using CDCl3/methanol-d4 as the solvent. MS analyses were performed on an Agilent Series
1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto, CA, USA). Column
chromatography was carried out on Merck silica gel 60 (230-400 mesh) and reversed phase C18.
Preparative TLC was carried out using silica gel GF plates (20 X 20 cm, thickness 0.25 mm).
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5.1.4.2. Fermentation, Extraction, and Isolation

The fungus, S. musiva (ATCC 52800) was obtained from the American Type Culture
Collection (Manassaas, VA, USA) and its fermentation was carried out as previously
described.96
The EtOAc extract (9.0 g) was chromatographed over a silica gel column using hexanes-CH2Cl2MeOH gradients as mobile phases to give 20 fractions. Fractions 12 and 13 were combined and
chromatographed over a reversed phase C18 column eluting with a gradient of 10 to 100%
MeCN-H2O to yield nine fractions. Subfraction 4 was recrystallized with MeOH to obtain
septoriamycin A (1, 100 mg) as the major active constituents. Fractions 18-20 from the original
extract were combined and purified on Sephadex LH-20 (MeOH) to give (+)-cercosporin (2, 10
mg).

Compound 1 : white crystals (MeOH); mp 220 ºC; [α]26D +201 (c, 0.4, CH3OH) mp and
[α]26D were consistent with reported96; 1H and 13C NMR data96 (see Chapter 3); HRESIMS [M H]- m/z 370.2012 (calcd for (C22H29NO4 - H)-, 370.2018 ).

Compound 2 : Red crystals (MeOH); mp 239 ºC (lit.110 240-241.5 ºC); 1H and 13C
NMR (see Chapter 4) were consistent with reported.98, 112 HRESIMS [M + H] + m/z 535.1651
(lit.112 [C24H33NO4 + H] + 535.1604).
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5.1.4.3. Biological Assays
Antiplasmodial,69 phytotoxic,70 antimicrobial71,72 and cytotoxic76 assays were carried out as
described.

112

PART 11: MALFORMIN A1 AN ANTIMALARIAL COMPOUND FROM PHOMOPSIS
VITICOLA (ASCOMYCOTA)
5.2.1. Summary

Malformin A1 was isolated as the active compound from an extract of Phomopsis viticola
with antiplasmodial and phytotoxic activities. Even though this compound was not cytotoxic to
Vero cells, it showed potent toxicity to a panel of mammalian cancer cell lines precluding it as a
potential antimalarial drug lead.

5.2.2. Introduction

P. viticola (Ascomycetes), the agent responsible for Phomopsis cane and leaf spot disease
in grapevines, causes serious yield loss. A variety of biologically active secondary metabolites
have been reported119-124 from this genus.
An EtOAc extract of P.viticola (ATCC 48153) in Czapex Dox medium showed potent herbicidal
and antiplasmodial activities with good selectivity. Bioassay-guided fractionation of this extract
led to the isolation of malformin A1 (3) as the active compound (Figure 6.2.1).
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Figure 5.2.1. Structure of malformin A1 (3)
5.2.3. Results and Discussion

P.viticola, (ATCC 48153) was grown in PDB, V8, solid rice, and Czapex Dox culture
media. Of those, an EtOAc extract of Czapex Dox culture broth showed potent herbicidal and
antiplasmodial activity with good selectivity index (Table 2.1). Bioassay-guided fractionation of
this extract by repeated column chromatography furnished malformin A1 (3) as the active
compound. The structure of this compound was confirmed by spectroscopic methods.125
Malformin A1, a cyclic pentapeptide (cyclo-D-Cys-D-Cys-L-Val-D-Leu-L-Ile) with a disulfide
bond between two cysteine moieties, has been isolated from plant pathogenic Aspergillus
species.125,
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The phytotoxic activity of this compound has extensively been studied.125,

127

Antiplasmodial and antitrypanosomal activities, and structure activity relationships of several
synthetic malformin analogues have been reported.128 Based on these results, the presence of a
disulfide bond is required for the biological activity of these compounds.128
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Malformin A1 (3) showed potent antimalarial activity with IC50 values in the range of
0.05-0.07 nM for W2 and D6 strains (Table 5.2.1) and strong phytotoxic (Table 5.2.3) activity.
Although this compound exhibited no toxicity to Vero cells at the highest concentrations tested
(4760 ng/mL), previous studies have shown it to be toxic to a panel of cancer cell lines.129
Evaluation of activity of malformin A1 (3) against a panel of human cancer cell lines (SK-MEL,
KB, BT-549, and SK-OV-3)

and mammalian kidney epithelial cells (LLC-PK11) showed

significant cytotoxicity to all the tested cell lines with IC50 values in the range of 2-4  except
for KB cells (9.5 Malformin A1 has shown high intraperitonial toxicity in mice (LD50 3.1
mg/kg); however, it had no oral toxicity at doses ≤ 50 mg/kg.126 This lack of oral toxicity may be
due to poor oral bioavailability of peptides.130

5.2.4. Bioactivity Results

Table 5.2.1. Antimalarial activity of 3

ChloroquineCompound

sensitive (D6)-clone
IC50 nM

Chloroquineresistant (W2)-clone

S.I.

IC50 nM

Cytotoxicity to
Vero cells

S. I.

IC50 nM

malformin A1(3)

0.07 >128.2

0.05 >178.0

NC

chloroquinea

0.07

0.88

NC

artimisinina

0.06

0.04

NC
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a

Positive controls

NC not cytotoxic
S. I. (selectivity index) = IC50 for cytotoxicity /IC50 for antiplasmodial activity
IC50: concentration causing 50% growth inhibition

Table 5.2.2. Cytotoxic activity [IC50 ()] of 3

Compound

a

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

malformin A1

2.83

9.45

3.12

4.91

3.11

doxorubicina

1.65

1.65

1.51

3.49

1.13

Positive control.

IC50 = concentration causing 50% growth inhibition
SK-MEL = human malignant melanoma
KB = human epidermal carcinoma
BT-549 = human breast carcinoma (ductal)
SK-OV-3 = human ovary carcinoma
LLC-PK11 = pig kidney epithelial
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Table 5.2.3. Phytotoxic activity of 3

Compound
Malformin A1

Concentration (mM)

Lettuce

Bentgrass

1.89

5

5

0.18

3

4

0.018

1

1

Ranking based on scale of 0 to 5
0 = no effect, 5 = no growth

5.2.5. Experimental

5.2.5.1. General

Melting points were measured with a Uni-melt, Thomas Hoover capillary melting point
apparatus. Optical rotations were measured using a Rudolph Research Analytical Autopol IV
automatic polarimeter model 589-546. NMR spectra were recorded on a Varian-Mercury-plus400 or Varian Unity-Inova-600 spectrometer using pyridine-d4 as the solvent unless otherwise
stated. MS analyses were performed on an Agilent Series 1100 SL equipped with an ESI source
(Agilent Technologies, Palo Alto, CA, USA). Column chromatography was carried out on Merck
silica gel 60 (230-400 mesh) and reversed-phase C18 silica gel. Preparative TLC was carried out
using silica gel GF plates (20 X 20 cm, thickness 0.25 mm).

117

5.2.5.2. Fermentation, Extraction, and Isolation

P. viticola (ATCC 48153) was obtained from the American Type Culture Collection
(Manassaas, VA, USA) and grown in PDA plates at 29 οC for 14 days. A flask (1L) with100 mL
of PDB was inoculated with agar pieces (0.25 in × 0.25 in) and incubated at 29 ºC for 8 days on
a shaker (RPM = 100). Erlenmeyer flasks (38 × 1L) each containing 500 mL of M-2 medium,
(modified Czapex Dox medium : Czapex Dox 35.0 g, yeast extract 1.5 g, malt extract 1.5 g in 1L
of distilled H2O) were inoculated with this seed culture and incubated at 29 ºC for 28 days on a
shaker (RPM = 100). The broth was separated by filtration and extracted with EtOAc (×3). The
organic layer was evaporated under reduced pressure to give an oily residue (3.0 g).
The oily extract (2.9 g) was chromatographed over Sephadex LH -20 and eluted with
100% MeOH to give 12 fractions. Fractions 4 and 5 which showed antiplasmodial activity (≤
528 ng/ml) were combined and chromatographed over a reversed-phase C18 column eluting with
a gradient of 10 to 100% MeCN-H2O to yield malformin A1 (7.0 mg).

Compound 3 : white amorphous powder (MeOH); mp 303 0C (lit.110 > 300 οC); [α]26D 28 (c, 0.5, CH3OH) ([α]26D -39 lit.128); 1H and

13

C NMR data were consistent with reported128

values; HRESIMS [M + H]+m/z 530.2418 (lit.128 [C24H33NO4 + H] + 530.2470)
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5.2.5.3. Biological Assays

Antiplasmodial,69 phytotoxic,70 and cytotoxic76 assays were carried out using the procedures as
previously described.
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CHAPTER 6: PHYTOTOXIC COMPOUNDS FROM THE WOOD ROTTING FUNGUS,
POSTIA BALSAMEA (BASIDIOMYCETES)

6.1. Summary

Postia balsamea is one of the causal agents of root rot and butt rot in balsam fir (Abies balsamea,
Pinaceae). Preliminary screening of the EtOAc extract of a fermentation broth of P. balsamea
showed antiplasmodial and phytotoxic activities. Bioassay-guided fractionation of the EtOAc
extract led to the isolation of four polyacetylenes, (2E,8E)-matricaria ester (1), (2E,8E)matricarianol (2), (2E,8E)-deca-2-8-diene-4,6-diyne-1,10-diol (3),

and (3S,8E)-methyl 3-

hydroxydeca-8-en-4,6-diynoate (4); one phenolic acid, (S)-3-(3,4-dihydroxyphenyl)lactic acid
(5); three halogenated phenolic acid analogues, (S)-3-(3,5-dichloro-4-hydroxyphenyl)lactic acid
(6), (S)-Methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate (7), and (S)-methyl 3-(3,5-dichloro-4methoxyphenyl)lactate (8); and four triterpenes, eboricoic acid (9), acetyleboricoic acid (10),
sulfurenic acid (11), dehydrosulfurenic acid (12), and a mixture of minor compounds which
showed good antiplasmodial activity. The structures of the pure compounds were determined by
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spectroscopic and spectrometric methods. Of these compounds, compounds 4 and 8 are new, and
compounds 6 and 7 have been synthesized, but this is the first report of their isolation from a
natural source. The conjugated polyacetylenes and halogenated phenolic compounds showed
strong phytotoxic activity against monocots (Agrostis stolonifera cv. Pencross) and dicots
(Lactuca sativa).

6.2. Introduction

Postia Fr (Aphyllophorales, Basidiomycota), a widespread genus of brown rot fungi in
North America, Europe, and China, has variable morphological characteristics and a wide range
of tree hosts including both hardwoods and conifers. 131-133 Species of this genus are also known
by several synonyms because of updates in nomenclature, among them Oligoporous, Postia,
Rhodonia, Spongipellis, Tyromyces, Polyporous, Polysticus, and Poria. 131-133
P. balsamea, an agent responsible for root rot and butt rot in balsam fir (Abies balsamea,
family Pinaceae), causes considerable economic damage. Balsam fir which grows in the northern
United States and Canada is extensively used for pulp and lumber and is also one of the most
popular Christmas trees. P. balsamea can enter roots and the basal area of trees through wounds
caused by insects or mechanical means and attack functional vascular and cambium tissues most
likely by releasing phytotoxins first and then depolymerizing enzymes to hydrolyze cellulose and
hemicelluloses.40, 135 Infected trees become susceptible to secondary attacks by insects and wind
damage.135 Thus far, no work has been reported on the chemical constituents of genus under the
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named “Postia”, although there is a possibility that Postia has been identified under another
synonym.
Preliminary screening of the EtOAc extract of the fermentation broth of P. balsamea
showed potent antiplasmodial and phytotoxic activities. Bioassay-guided fractionation of this
extract afforded a fraction with potent activity and good selectivity. Although the EtOAc extracts
of the subsequent large-scale fermentation broths showed potent phytotoxic activity against
monocots (Agrostis stolonifera cv. Pencross) and dicots (Lactuca sativa), they were devoid of
antiplasmodial activity. Thin layer chromatographic analysis of the active fraction showed two
major and four minor spots. By comparison with the inactive fractions all but one could be
eliminated as the possible active constituent (Figure 6.1). Compounds in P. balsamea broth
belong to three different chemical classes: C-10 polyacetylenes, phenyllactic acid analogues, and
lanostane triterpenes. Spectroscopic analysis indicated that constituents only present in the active
fraction by TLC analysis did not to belong to any of these classes.

6.3. Results and Discussion

Preliminary small-scale culture of P. balsamea (ATTC 64899) in PD broth produced an
extract with high antiplasmodial activity but no cytotoxicity. Although the EtOAc extracts of the
large scale fermentation broth showed TLC profiles similar to the original extract, it was devoid
of antiplasmodial activity. Re-culture of the fungus with the same and different culture media
[Czapex dox, V-8 (100% vegetable juice), and rice] and a new sample of the fungus from the
ATCC, cultured under original conditions, failed to produce an extract with antiplasmodial
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activity. Attempts were also made to produce active metabolites by inoculating the culture
medium with the bark and leaf parts of Abies balsamea as elicitors. Fractionation of the original
active extract yielded a fraction (15 mg) with potent selective activity. TLC analysis revealed a
spot in the active fraction which was only present in that fraction (Figure 6.1).

Figure 6.1. TLC comparison of antimalarial active fraction with inactive fractions and
compounds

Since the compound or compounds corresponding to this spot could be derivatives of the
other compounds present in the extracts, all constituents in the extracts were isolated and
identified to facilitate the identification of the active compounds.
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EtOAc extracts of broth and mycelia of P. balsamea were fractionated by repeated silica
gel column chromatography, and the compounds were purified by PTLC to afford
polyacetylenes (1-4), four phenolic compounds (5–8), and four triterpene acids (9-12) as shown
in Figure 6.2. Compounds 4 and 8 are new, and compounds 6 and 7 have previously been
synthesized.136 The known compounds, (2E,8E)-matricaria ester (1),137 (2E,8E)-matricarianol
(2),137 (2E,8E)-deca-2-8-diene-4,6-diyne-1,10-diol (3),137,

138

(S)-3-(3,4-dihydroxyphenyl)lactic

acid (5),139 (S)-3-(3,5-dichloro-4-hydroxyphenyl)lactic acid (6),136 (S)-methyl 3-(3,5-dichloro-4methoxyphenyl)lactic acid (7),136 eboricoic acid (9),

140

acetyl eboricoic acid (10),140 sulfurenic

acid (11),141 and dehydrosulfurenic acid (12)141 were identified by comparing observed and
published spectroscopic data.

124

Figure 6.2. Structure of compounds isolated from P. balsamea
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Compound 4 was obtained as an amorphous powder. The IR spectrum of 4 showed
absorption at 3435 cm-1 due to a hydroxy group and at 1728 cm-1 due to a carbonyl group. The
UV spectrum showed characteristic absorptions at 206, 228, 253, 268, and 284 nm, indicating
the presence of an ene-diyne chromophore.142 The 1H NMR spectrum (Figure 6.3) showed spin
systems for a methyl-substituted trans-olefinic bond [δH (1H) 6.34 dq J = 16.0, 7.2 Hz, δH 5.52
(1H) brd J = 16.0 Hz, and δH 1.82 (CH3) dd 7.2, 1.6 Hz], similar to that observed for compound
1,137 a hydroxymethine adjacent to a methylene [δH (1H) 4.85 t J = 6.0 Hz, δH (2H) 2.76 d, J =
6.0 Hz], and a methoxy group (δH 3.76). The
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C NMR spectrum (Figure 6.4) of 4 showed 11

resonances indicating four acetylenic carbons (δC 80.1, 78.4, 71.5, and 70.2), two olefinic
carbons (δC 109.6, 144.7), one oxymethine carbon (δC 59.4), one methoxy carbon (δC 52.3), one
ester carbonyl carbon (δC 171.6), and one methylene carbon (δC 41.6). In the HMBC spectrum
(Figure 6.5), H-9 showed correlations with the methyl group, C-10, and C-7 (δC 78.4). The -CH3
protons (δH 1.80) showed correlations with C-9 (δC 144.7), C-8 (δC 109.6), C-7 (δC 78.4), and C-6
(δC 71.5). The oxymethine proton at C-3 showed long range correlations to the carbonyl group
(δC 171.6), C-4 (δC 80.1), C-5 (δC 70.2), and C-2 (δC 41.6); whereas, the methylene doublet at δH
2.76 correlated with the carbonyl (δC 171.6), C-3 (δC 59.4), and C-4 (δC 80.1). The methoxy
group (δH 3.76) had an HMBC correlation with the carbonyl group. These correlations, as
indicated in Figure 6.6, supported the proposed structure as methyl 3-hydroxydeca-8-en-4,6diynoate (4). The absolute configuration at C-3 was determined based on specific rotation. The
reported specific rotations for (3R)- and (3S)-3-hydroxypent-4-ynoic acid methyl esters are
+24.5143 and -19.2,144 respectively. The specific rotation of compound 4 was -14.5; thus, the
absolute configuration of C-3 was assigned as S.
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Figure 6.3. 1H NMR spectrum of 4

Figure 6.4.

13

C NMR spectrum of 4
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Figure 6.5. HMBC spectrum of 4

Figure 6.6. COSY (

) and HMBC (

) correlations of 4

The NMR spectra of 8 were superimposable with those of 7 except for the presence of an
additional resonance for a methoxy group in the spectra of the former (Figure 6.7). Methylation
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of compound 7 with trimethylsilyldiazomethane yielded a product which had the same physical
and spectroscopic data (Figures 6.7 and 6.8) as those for 8, confirming that the latter was (S)methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate.
The active fraction from the original extract was separated by column chromatography to
afford a subfraction which appeared to be a single compound by TLC. The 1H NMR spectrum
indicated that it was a mixture of closely related compounds. This subfraction was further
separated by HPLC to yield four compounds in minute amounts. The 1H NMR data of these
compounds indicated that they did not belong to any class of compound isolated from these
extracts. Owing to lack of material, their structure elucidation was not feasible.
Compounds 1, 2, and 3 showed significant phytotoxic activity against both dicots
(lettuce, Lactuca sativa) and monocots (bentgrass, Agrostis stolonifera) (Table 6.1). A number
of conjugated polyyne compounds have been isolated from higher plants,145-148 and
basidiomycetes,137,

149

and exhibited a variety of biological activities.142,

145, 150, 151

Geometric

isomers of compound 1 have been isolated from Chrysoma pauciflosculosa and their
phytotoxicity as well as allelopathic effects on some Florida sandhill scrub species have been
reported.148
Compounds 5, 6, and 8 exhibited good phytotoxic activity against both dicots (lettuce,
Lactuca sativa) and monocots (bentgrass) (Table 6.1). Compounds 1-8 showed no activity in
antimicrobial and antiprotozoal assays.
Compound 5, the S enantiomer, is a rare natural product. Its R enantiomer, salvianic acid
A, has been isolated from Salvia miltiorrhiza root, which is widely used in traditional medicine
for the treatment of various cardiovascular diseases
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number of natural products including rosmarinic acid.139
129

and is also a biosynthetic precursor to a

Compounds 6 and 7 have not been isolated from natural sources. They have been found
as precursors to compounds isolated from a cyanobacterium136 and have been synthesized.

Figure 6.7. 1H NMR spectrum of 8
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Figure 6.8.

A

number

basidiomycetes.142,

of
153, 154

13

C NMR spectrum of 8

chlorinated

phenolic

compounds

have

been

isolated

from

Some of these compounds have shown antimicrobial155 and seed

germination inhibitory156 activities. They also have been reported157, 158 to be involved in lignin
degradation25,26 and inhibition of the enzyme chitin synthase.29
Lanostane triterpenes have been isolated from several fungal species of the Polyporaceae,
and their antioxidant and cytotoxic activities have been reported.140,

159-161

Compounds 9-12

showed no activity in antimicrobial, antiprotozoal, and phytotoxic assays.
The variation in metabolite production in culture media and from one culture flask to
another within the same media has been reported45, 119 from several fungi. The failure to produce
the antiplasmodial metabolites in large-scale culture broths may be due to the loss of virulence
factors and/or specific virulence genes involved in the synthesis of specific toxins, upon

131

continuous subculturing of the fungus. It may also be due to mutation of genes responsible for
biosynthesis of the specific toxins.

6.4. Experimental
6.4.1. General

Optical rotations were obtained using a Rudolph Research Analytical Autopol IV automatic
polarimeter model 589-546. Melting points were measured with a Uni-melt, Thomas Hoover
capillary melting point apparatus. UV and IR spectra were determined on a Varian-50 Bio UV
visible spectrophotometer and a Bruker-Tensor-27 infrared spectrophotometer, respectively.
NMR spectra were recorded on a Varian-Mercury-plus-400 or Varian Unity-Inova-600
spectrometer using CDCl3/CD3OD as the solvent unless otherwise stated. MS analyses were
obtained from an Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies,
Palo Alto, CA, USA) and GCMS (Hewlett-Packard 6890 series). Column chromatography and
preparative TLC were carried out using Merck silica gel 60 (230-400 mesh) and silica gel GF
plates (20 × 20 cm, thickness 0.25 mm), respectively. TLC spots were detected under UV
irradiation and by heating on a hot plate after spraying anisaldehyde reagent. HPLC analysis was
conducted on a Hewlett-Packard Agilent 1100 with diode array detector. Potato dextrose agar
(PDA), potato dextrose broth (PDB), and Czapex dox were purchased from DifcoTM. V-8 and
rice were purchased from Walmart in Oxford, MS. Postia balsamea (ATCC 64899) was
obtained from the American Type Culture Collection (ATCC).

132

6.4.2. Fermentation and Extraction

P. balsamea obtained from the ATCC was grown on PDA plates at 27 ºC for 12 days.
Erlenmeyer flasks (2 × 1 L) containing 600 mL of PDB were inoculated with three small agar
pieces (5 × 5 mm) containing P. balsamea and were incubated at 27 ºC for 28 days on a shaker
(RPM = 100). The culture broth and mycelia were filtered. The broth was extracted with EtOAc
(× 3), and the organic layer was evaporated under reduced pressure to give an oily residue (189.0
mg). Mycelia were extracted with MeOH (× 3) and evaporated to give a brown oily residue (200
mg). These extracts showed good phytotoxic and antimalarial activities.
Scale up of fermentation was carried out (× 3) by repeating the above procedure with
identical conditions using Erlenmeyer flasks (40 × 1L) to obtain EtOAc broth extracts (3.8, 3.5,
and 3.7 g) and mycelia extracts (4.1, 4.8, and 3.4 g). These extracts exhibited good phytotoxic
activities but were inactive in the antimalarial assay.
Fermentation was carried out in several other culture media [V8 (100% vegetable juice),
Czapex dox, and Rice] and under various conditions such as different volume of broth (100 , 250
, and 500 mL), different Erlenmeyer flask sizes (250, 500 mL, and 1 L), and different
fermentation time periods (2, 3, 4, and 5 weeks). Fermentations were also carried out in the
presence of small amounts of the bark and leaf parts of a fir tree; however, the above
experiments, as well as a fresh P. balsamea sample from the ATCC under the original culture
conditions, failed to produce extracts with antimalarial activity.
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6.4.3. Attempted Isolation of Antimalarial Compounds

The original oily extract (189 mg) which showed good antiplasmodial activity (IC50 < 1
µg/mL against P. falciparum) and good phytotoxic activity was chromatographed over a gravity
column using hexanes, CH2Cl2, and MeOH as the eluents to give seven subfractions. Fraction 3
(18.0 mg) showed potent antiplasmodial activity (IC50 < 120 ng/mL) with high selectivity. TLC
analysis of this fraction showed the presence of two major and four minor spots (Figure 6.1). The
active fraction was separated using a reversed-phase Luna C18 column (1 × 25 cm) and eluted
with MeOH-H2O (65:35) as the mobile phase at a flow rate of 2.5 mL/min, with wave length set
at 254 nm. The major compounds corresponding to the major spots were also present in
substantial amounts in the large-scale extracts as well as in mycelia extracts. They were isolated
from mycelium extract and identified as eboricoic acid (9) and sulfurenic acid (11) (vide infra).
These compounds were inactive in the antiplasmodial assay. HPLC analysis revealed that the
minor spot consisted of at least four related compounds, and their identification was not possible
due to insufficient quantities.

Polyacetylenes

The EtOAc extract of the large scale fermentation broth (3.8 g) which showed potent
phytotoxic activity against monocots (Agrostis stolonifera cv. Pencross) and dicots (Lactuca
sativa) was fractionated by silica gel column chromatography using hexanes, CH2Cl2, and
MeOH as eluents to give eighteen fractions. Fractions 1, 2, and 3 showed potent phytotoxic
activity against both monocots and dicots. The compounds present in these fractions showed a
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tendency to undergo decomposition. Fraction 1 (50.0 mg) was chromatographed over a gravity
column using hexanes as the eluting solvent, and further separation was carried out by PTLC
using 15% EtOAc in hexanes to yield (2E,8E)-matricaria ester (1)137 (8.0 mg). Fractions 2 and 3
were combined and subjected to silica gel gravity column chromatography using hexanes and
CH2Cl2 as the eluents to yield 9 fractions. Subfraction 8 (130 mg) was applied on Sephadex LH20 and eluted with 100% MeOH to give (2E,8E)-matricarianol (2)137 (5.0 mg). Subfraction 9
was applied on Sephadex LH-20 and eluted with 100% MeOH followed by PTLC using 30%
EtOAc in hexanes as developing solvent to yield (2E,8E)-deca-2-8-diene-4,6-diyne1,10-diol
(3)137, 138 (1.0 mg) and (3S,8E)-methyl 3-hydroxydeca-8-en-4,6-diynoate (4) (2.0 mg).

Phenolic Compounds
Fractions 4 and 5 were combined and chromatographed over a silica gel gravity column
followed by PTLC using 35% EtOAc in hexanes as the developing solvent to give three simple
phenolic compounds, 5 (S)-3-(3,4-dihydroxyphenyl)lactic acid (2.0 mg), 6 (S)-3-(3,5-dichloro-4hydroxyphenyl)lactic acid (7.0 mg), and 7 (S)-methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate
(10.0 mg). Compound 8 (S)-methyl 3-(3,5-dichloro-4-methoxyphenyl)lactate (10.0 mg) was
isolated as white crystals from fraction 12 (CH2Cl2/MeOH).

Triterpenes

Fractions 13 and 14 were combined and chromatographed over a silica gel column using
hexanes and EtOAc as eluents to give eboricoic acid (9, 1.0 mg) and acetyl eboricoic acid (10,
2.0 mg) as white amorphous powders. The mycelia extract (12.0 g) was chromatographed over
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a silica gel column using hexanes, CH2Cl2, and MeOH as the eluents to give nine fractions.
Further purification of these fractions using repeated column chromatography furnished
triterpenes 9 (5.0 mg) and 10 (10.0 mg) and a mixture of the two triterpenes 11 and 12. NMR and
HRESIMS data of the mixture confirmed them to be sulfurenic acid (11) and dehydrosulfurenic
acid (12).

Compound 4 : amorphous, [α]26D – 14.5 (c 0.1, CHCl3); IR max 3435, 1728 cm-1; UV (CHCl3):
λmax (log ε) 206 (3.20), 228 (3.33), 253 (3.22), 268 (3.20), and 284 (3.14) nm; ESIMS [M - H]+ :
m/z = 174; 1H NMR: 1.82 (3H, dd, J = 7.2, 1.6 Hz, H-10), 2.77 (2H, d, 6.0 Hz, H-2)), 3.74
(3H, s, OCH3), 4.85 (1H, t, J = 6.0 Hz, H-3), 5.52 (1H, d, J = 15.2 Hz, H-8), 6.34 (1H, dq, J =
16.0, 7.2Hz, H-9),

13

C NMR: 19.2 (C-10), 41.6 (C-2), 52.4 (-OCH3), 59.4 (C-3), 70.2 (C-5),

71.5 (C-6), 78.4 (C-7), 80.1 (C-4), 109.6 (C-8), 144.8 (C-9), 171.6 (C-1)

Compound 8 : White solid, mp 80o C, [α]26D -11 (c 0.1, CHCl3); IR max 3468, 1736 cm-1; UV
(MeOH) λmax (log ε): 225 (3.91), 275 (3.19) nm; EIMS [M + H]+ m/z 279. HRESIMS [2M + H +
Na]+ m/z 581.0403 (calcd for (C22H25Cl4O8Na) 580.0201); 1H NMR  2.7 (1H, dd, J = 14.0, 7.2
Hz, H-3), 2.87 (1H, brd, J = 14.0 Hz, H-3), 3.31 (3H, s, OCH3), 3.64 (3H, s, COOCH3), 4.29
(1H, brs, H-2), 7.00 (2H, s, H-2′ and H-6′);

13

C NMR:  39.2 (C-3), 52.7 (OCH3), 60.7

(COOCH3), 70.7 (C-2), 129.0 (C-1′), 129.9 (C-2′, 6′), 134.1 (C-3′ and C-5′), 151 (C-4′).
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Methylation of Compound 7:

Compound 7 (2 mg) in methanol (0.5 ml) was treated with trimethylsilyldiazomethane (50 L) at
room temperature for 10 minutes. Solvent was evaporated and the residue was dissolved in
CH2Cl2, and filtered through a plug of celite® to yield compound 8 (2.1 mg).

6.4.4. Biological Assay

6.4.4.1. Antiplasmodial Activity

The antiplasmodial activity of extracts, fractions and pure compounds was performed
against D6 (chloroquine sensitive) and W2 (chloroquine resistant) strains of P. falciparum using
the in vitro assay as reported.69

6.4.4.2. Phytotoxic Activity

The herbicidal activity of extracts and test compounds was performed using the
procedure described by Dayan et al.111 using bentgrass (Agrostis stolonifera) and lettuce
(Lactuca sativa cv. L., Iceberg), in 24-well plates. The results are collated in Table 6.1.
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Table 6.1. Phytotoxic activity of P. balsamea compounds

Concentration
Compound

(mM)

Lettuce

Bentgrass

5.7

5

4

0.6

1

0

6,8

5

5

0.7

4

3

5.2

5

5

0.52

1

0

4

-

NT

NT

5

3.6

5

4

0.36

0

0

5.1

4

4

0.5

0

0

7

-

NT

NT

8

4.0

5

5

0.4

0

0

9

2.1

NA

NA

10

1.9

NA

NA

11

2.1

NA

NA

12

2.1

NA

NA

1

2

3

6

Ranking based on scale of 0 to 5
0 = no effect, 5 = no growth
NT = Not tested
NA = Not active
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CHAPTER 7: ANTIMALARIALS FROM ENDOPHYTIC FUNGI ISOLATED FROM
TORREYA TAXIFOLIA ARNOTT

Torreya taxifolia Arn., an evergreen tree of the family Taxaceae, known as Florida
torreya, stinking-cedar, or gopherwood, can grow to heights up to 20 meters.162 The native
population decline during the last decades has been attributed to both abiotic and biotic causes
including fungal diseases.162 T. taxifolia is considered the rarest conifer in North America and is
one of the most endangered trees in the world.162 The symptoms of disease include needle spot,
needle death, needle cankers, defoliation, and stem lesions.163 This tree is in the same plant
family as Taxus brevifolia (Pacific yew) that produces taxol and taxane derivatives.164 Although
several studies have been carried out to determine the causative agent responsible for the rapid
decline of the plant, the identity of a single highly virulent pathogen remains an area of active
research, with a Fusarium being the most recently reported causative agent.162, 163 Pathogenicity
studies carried out in the past few years, concluded that several pathogens may be responsible for
leaf spots, but not for the canker disease. These pathogens included163, 165, 166 Macrophoma sp.,
Rhizoctonia solani, Sphaeropsis sp., Sclerotium rolfsii, Fusarium lateritium, and Pestalotiopsis
microspora.
From T. taxifolia nine endophytic fungi were isolated from diseased leaves of cultivated
plants (Figures 7.1 and 7.2), and six endophytic fungi were isolated from diseased seeds.
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EtOAc extracts of fermentation cultures of these fungi were screened for phytoxic
activity against both a dicot (lettuce, Lactuca sativa L.) and a monocot (bentgrass, Agrostis
stolonifera L.) and antiplasmodial activity against chloroquine-sensitive (D6) and -resistant (W2)
strains of P. falciparum. Of the endophytes screened, Xylaria sp. (Section 7.1), Alternaria sp.
(Section 7.2), a new isolate, UM #10 M (Section 7.3), and Botryosphaeria dothidea (Section 7.4)
showed good antiplasmodial and phytotoxic activities (Table 7.1).

Figure 7.1. Symptoms of diseased needles of cultivated T. taxifolia
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Figure7.2. Symptoms of diseased needles of cultivated T. taxifolia
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Table 7.1: Antiplasmodial and herbicidal activity of endophytic fungi extracts

Antiplasmodial activity

Cytotoxicity

IC 50 (ng/mL)

Fungi

Medium

Phytotoxicity

(vero)

P.

P.

IC 50

falciparum

falciparum

(ng/mL)

D6 clone

SI

W2 clone

SI

Lettuce Bentgrass

Botryosphaeria dothidea
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(Broth)

PDB

860

37.2

1300

24.6

32000

5

5

Xylaria sp (Broth)

PDB

62

3.3

87

2.3

200

5

5

UM #10 M (Broth)

PDB

40

170

44

154.5

6800

5

5

PDB

6800

1.8

5800

2.1

12000

5

5

Alternaria sp. (Broth +
Mycelium)

Ranking based on scale of 0 to 5
0 = no effect, 5 = no growth
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SECTION 7.1: ANTIMALARIALS FROM XYLARIA SP.

7.1.1. Summary

Bioassay-guided fractionation of the potato dextrose culture broth extract of Xylaria sp. isolated
from a diseased leaf of Torreya. taxifolia afforded a known compound, heptelidic acid (1), as the
active constituent. This compound showed good antiplasmodial activity and phytotoxicity, but
was also cytotoxic to vero cells and a panel of solid tumor cell lines.

Figure 7.1.1. PDA plate of Xylaria sp.
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7.1.2. Introduction

Xylaria sp. is also known as Stag's Horn and Candle-snuff. Its morphology (Figure 7.1.1)
shows it contains antler-like ascocarps (fruit bodies) which are black at the base and, white and
branched towards the top where the fruit bodies produce white conidia (asexual spores). This is a
cosmopolitan fungal genus belonging to the family Xylariaceae and several members of this
family have been reported168-177 to produce a number of chemically diverse, biologically active,
and taxonomically significant constituents, including several antimalarial compounds.57, 178, 179
An EtOAc extract of the fermentation culture broth of Xylaria sp. showed potent
herbicidal and antiplasmodial activities. Bioassay-guided fractionation of this extract afforded
heptelidic acid (1), as the active compound.

7.1.3. Results and Discussion

This fungus was identified to be a Xylaria sp. by its characteristic morphological features
and the DNA sequencing profile of the fungal internal transcribed spacer (ITS) region.68 The
active EtOAc extract was fractionated by repeated silica gel column chromatography, and
compounds were further purified with Sephadex LH-20 to afford heptelidic acid (1) (Figure
7.1.2) as the antiplasmodial and phytotoxic constituent. Its identity was confirmed by
comparison of the physical and spectroscopic data with those reported.180 This sesquiterpene
lactone has been isolated180 from Trichoderma viride, Chaetomium globsum, and Gliocladium
virens, by Itoh et al., and was demonstrated to possess antiplasmodial activity.67
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Figure 7.1.2. Heptelidic acid (1)

Heptelidic acid (1) exhibited moderate antiplasmodial activity (Table 7.1.1) but also
showed cytotoxicity against Vero cells (Table 7.1.1), kidney epithelial cells, and a panel of solid
tumor cell lines (Table 7.1.3). This compound showed moderate phytotoxic activity against a
dicot (Table 7.1.2). The observed general cytotoxicity precludes heptelidic acid as a viable
antimalarial drug lead.
7.1.4. Biological Activities

Table 7.1.1. Antiplasmodial activity of 1

Chloroquine-

Chloroquine-resistant

Cytotoxicity

sensitive (D6)-clone

(W2)-clone

to Vero cells

IC50 nM

S. I.

IC50 nM

S. I.

IC50 nM

heptelidic acid (1)

0.30

2.0

0.27

2.3

0.61

chloroquinea

0.03

496.6

0.31

48.1

NC

artemisinina

0.02

845

0.01

1690

NC

Compound

145

a

Positive controls

NC, not cytotoxic
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity

Table 7.1.2. Phytotoxic activity of 1

Compound

Lettuce

Bentgrass

heptelidic acid (1)

4

1

Ranking based on scale of ο to 5
0 = no effect
5 = no growth
Solvent used, 10% acetone
Concentration used, 1mg/mL

Table 7.1.3. Cytotoxic activity [IC50 (µM)] of 1

Compound

a

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

heptelidic acid (1)

2.67

3.21

3.4

11.8

2.32

doxorubicina

1.29

2.12

1.83

1.47

1.28

Positive control.

IC50 = concentration casusing 50% growth inhibition
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SK-MEL = human malignant melanoma
KB = human epidermal carcinoma
BT-549 = human breast carcinoma (ductal)
SK-OV-3 = human ovary carcinoma
LLC-PK11 = pig kidney epithelial

7.1.5. Experimental

7.1.5.1. General

Melting points were measured on a Unimelt, Thomas-Hoover capillary melting point
apparatus. NMR spectra were recorded on a Bruker 400 MHz spectrometer using
CDCl3/methanol-d4 as the solvent unless otherwise stated. MS analyses were performed on an
Agilent Series 1100 SL equipped with an ESI source (Agilent Technologies, Palo Alto, CA).
Column chromatography was carried out on Merck silica gel 60 (230-400 mesh) and Sephadex
LH-20. Preparative TLC was carried out using silica gel GF plates (20 × 20 cm, thickness 0.25
mm). HPLC analysis was conducted on a Hewlett-Packard Agilent 1100 with diode array
detector.

7.1.5.2. Isolation of Xylaria sp. from T. taxifolia

Diseased leaves were collected from a cultivated T. taxifolia plant. Leaves were surface
sterilized with 5% Chlorox for 5 minutes and rinsed with sterile water three times. Transverse
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sections from the dried leaf were cut aseptically into small portions and immersed in the potato
dextrose plates. The plates were incubated for two weeks, and fungal colonies were subcultured
to PDA plates to isolate pure fungal Xylaria sp.

7.1.5.3. Fermentation, Extraction, and Purification

Xylaria sp. was cultured in two conical flasks (1 L) containing 500 mL of Potato
Dextrose Broth and incubated at 27 ºC for 18 days on an orbital shaker at 100 rpm. The media
was separated by filtration. The culture broth was extracted with EtOAc (× 3), and the organic
layer was evaporated to give an oily residue (410 mg).
The oily extract (400 mg) was chromatographed over a silica gel gravity column using
hexanes, CH2Cl2, and MeOH gradients as mobile phase to give 12 fractions. Fractions 5-9, which
showed antiplasmodial activity, were combined, chromatographed over Sephadex LH-20, and
washed with 100% MeOH to give heptelidic acid (1, 12.0 mg).

Compound 1 : Heptelidic acid; white powder; 1H and 13C NMR were consistent with
those reported.180 [α]26D +2.5 (c 0.28, CHCl3) lit180 +7.7; HRESIMS [M + H] + m/z 281.1422
(calcd for [C24H33NO4 + H] + m/z 281.1389)

7.1.5.4. Biological Assay

148

7.1.5.4.1. Antiplasmodial Assay

In vitro antiplasmodial activity against D6 (chloroquine sensitive) and W2 (chloroquine
resistant) strains of Plasmodium falciparum was determined as described earlier.69

7.1.5.4.2. Phytotoxic Assay

The bioassay for phytotoxicity was carried out according to the procedure described by Dayan et
al.70 using bentgrass (Agrostis stolonifera) and lettuce (Lactuca sativa L.cv. “Iceberg”), in 24well plates.

7.1.5.4.3. Cytotoxicity Assay

In vitro cytotoxicity was determined against a panel of mammalian cells as described earlier.76
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SECTION 7.2: ANTIMALARIALS FROM ALTERNARIA SP.
7.2.1. Summary

An Alternaria strain isolated from a diseased leaf of T. taxifolia exhibited antiplasmodial
and phytotoxic activities. Bioassay-guided fractionation of this extract afforded orsellinic acid
(2), penicillic acid (3), and a diastereomeric mixture of two new compounds, 6-hydroxy-5,6dihydropenicillic acid (4). Penicillic and orsellinic acids showed strong phytotoxic activity and
the former showed weak antiplasmodial activity.

7.2.2. Introduction

Figure 7.2.1. PDA plate of Alternaria sp.
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The genus Alternaria is widely distributed and a number of its species are known as plant
pathogens.181 Although several diverse secondary metabolites have been reported from
terrestrial,181 marine,182 and endophytic Alternaria sp., no antimalarial compounds have yet been
reported. The EtOAc extract of the broth and mycelia of this fungus had similar chemical
profiles and showed weak antiplasmodial activity against chloroquine-sensitive (D6) and resistant (W2) strains of P. falciparum and potent phytotoxic activity against both a dicot
(lettuce, Lactuca sativa) and a monocot (bentgrass, Agrostis stolonifera). Bioactivity-guided
fractionation of the combined extracts afforded orsellinic acid (2), penicillic acid (3), and a
diastereomeric mixture of two new compounds, 6-hydroxy-5,6-dihydropenicillic acid (4)

.

orsellinic acid (2)

penicillic acid (3) 6-hydroxy-5,6-dihydropenicillic acid (4)

4a

4b

Figure 7.2.2. Compounds isolated from Alternaria sp.
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7.2.3. Results and Discussion

An Alternaria strain was isolated from a diseased leaf of T. taxifolia. Identification of this
fungus was based on the DNA sequencing profile of the fungal internal transcribed spacer (ITS)
region.68 The active extract was fractionated over silica gel and the active fractions were
separated on Sephadex LH-20 to yield orsellinic acid (2), penicillic acids (3), and compound 4.
The identities of orsellinic (2)183 and penicillic acids (3)184 were confirmed by comparing their
physical and spectroscopic data with those reported.
Compound 4 was obtained as a white semisolid, and its molecular formula was assigned
as C8H12O5 by HRESIMS. The 1H (Figure 7.2.3) and

13

C NMR (Figure 7.2.4) data of 4 clearly

showed the presence of two related compounds in the ratio of approximately 1:2 (Table 7.2.1).
Comparison of spectroscopic data of 4 with those of penicillic acid (3) indicated that they were
closely related and that the vinyl group of the later has been replaced by a -CHCH2OH group
creating an stereogenic center. As in the case of penicillic acid, this compound also forms
epimeric lactols (Figure 7.2.5); however, due to the presence of the additional stereogenic center,
compound 4 comprises two diastereomers. COSY (Figure 7.2.6), and HMBC correlations
(Figure 7.2.7), were used to assign the resonances of both diastereomers, 4a and 4b (Figure
7.2.8). In the COSY spectrum, both the oxygenated methylene (H-6) and the methyl doublet (H7) had crosspeaks with the upfield methine multiplet (H-5). In the HMBC spectrum, oxygenated
methylene (H-6) showed correlations to C-4, C-5, and C-7 supporting the structure proposed for
this compound. Additional correlations shown in Figure 7.2.8 further support this structure. A
molecular mechanics energy minimization method showed 4a, as depicted in Figure 7.2.9, or its
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enantiomer to be the more stable conformer. The absolute configuration at C-5 remains to be
determined.
Orsellinic acid has previously been isolated from lichens183 and several fungi species.

185

This compound showed good phytotoxicity (Table 7.2.2). Anti-oxidant,183 antibacterial,186 and
growth inhibitory187 activities of orsellinic acid have been reported. Penicillic acid has been
reported188-190 from several fungi and is known to be cytotoxic to mammalian cells. Penicillic
acid showed weak in vitro antiplasmodial activity against chloroquine-sensitive (D6) and resistant (W2) strains of Plasmodium falciparum (Table 7.2.3) and good phytotoxic activity
against both a monocot and a dicot (Table 7.2.2). Phytotoxic activity of penicillic acid against
radical growth of Amaranthus hypochondriacus has been reported.191 Orsellinic acid is the
intermediate for the biosynthesis of penicillic acid derivatives.184

Figure 7.2.3. 1H NMR spectrum of 4
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Figure 7.2.4. 13C NMR spectrum of 4

4a
6-Hydroxy-5,6-dihydropenicillic acid

Figure 7.2.5. Formation of C-4 diastereomers (4a >4b, 2:1)
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4b

Figure 7.2.6. COSY spectrum of 4

Figure 7.2.7. HMBC spectrum of 4
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Figure 7.2.8. COSY (

) and HMBC (

) correlations of 4

4a

4b

Figure 7.2.9. Energy minimized structures (4a > 4b; 2:1)
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Table 7.2.1.

1

H and 13C NMR of 3, 4a and, 4b in CDCl3- Methanol-d4

penicillic acid (3)
δH a (J in Hz)
δCb
171.6
5.48, s
88.8
179.0
105.9
38.3
5.12, s, 5.22, s
63.4
1.77, s
10.6
3.91, s
59.4

Carbon
δC
1
2
3
4
5
6
7
8
a1

b

172.0
89.1
179.4
116.5
139.3
116.5
17.1
59.9

4a
δH a (J in Hz)

4b
δH a (J in Hz)

δCb
171.6
88.7
180.2
104.8
41.1
62.7
10.6
59.3

4.85, s

2.05, m
3.63, m
0.5, d (8.0)
3.67, s

H NMR recorded at 400 MHz, b13C NMR spectra recorded at 100 MHz

7.2.4. Biological Activities

Table 7.2.2. Phytotoxic activity of 2-4

Compound

Lettuce

Bentgrass

orsellinic acid (2)

5

5

penicillic acid (3)

4

5

6-hydroxy-5,6-dihydropenicillic acid (4)

1

3

Ranking based on scale of ο to 5
0 = no effect 5 = no growth
Solvent used, 10% acetone
Concentration used, 1mg/mL
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4.82, s

1.91, m
3.48, m
0.50, d (8.0)
3.64, s

Table 7.2.3. Antiplasmodial activity of 2-4

Chloroquine-

Chloroquine-

sensitive (D6)-clone

resistant

Compound

Cytotoxicity

(W2)- to Vero cells

clone
IC50 nM

orsellinic acid (2)

NA

penicillic acid (3)

17.1

6-hydroxy-5,6-

NA

S. I.

IC50 nM

S. I.

NA
>1.6

15.9

IC50 nM
NC

>1.7

NA

NC
NC

dihydropenicillic acid (4a &
4b)

a

chloroquinea

0.03

496.6

0.31

48.1

NC

artemisinina

0.02

845

0.01

1690

NC

Positive controls

NC, not cytotoxic
NA, not active
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity
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7.2.5. Experimental
7.2.5.1. General

Carried out as previously described in the section 7.1.4.1

7.2.5.2. Isolation of Alternaria sp.

Alternaria sp. was isolated as described in the Section 7.1.5.2

7.2.5.3. Fermentation, Extraction, and Purification

Alternaria sp. was cultured in four conical flasks (2 L) containing 500 mL of PDB and
incubated at 27 οC for 21 days on an orbital shaker at 100 rpm. The mycelium was separated by
filtration, and then the broth was extracted with EtOAc (× 3) separately. The organic layer of the
broth was evaporated to give a brown residue (1.85 g).
The brown extract (1.8 g) was chromatographed over a silicagel column using hexanes,
CH2Cl2, and MeOH gradients as mobile phase to yield nine fractions. Further separation of the
active fractions (5-8) by Sephadex LH-20 gel filtration (100% MeOH) afforded orsellinic acid
(2, 30.0.0 mg), penicillic acid (3, 15 mg), and a diastereomeric mixture of two new compounds,
6-hydroxy-5,6-dihydropenicillic acid (4a and 4b, 6.0 mg).

Compound 2 : Orsellinic acid; 1H ,13C NMR, and HRESIMS were consistent with reported
data.183
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Compound 3 : Penicillic acid; colorless crystalline solid (MeOH); mp 80 οC (lit190 82-85 οC)
1

H190 and 13C NMR184 were consistent with literature values.

Compound 4 : 6-Hydroxy-5,6-dihydropenicillic acid; amorphous powder; 1H and 13C NMR (see
Table 7.2.1) HRESIMS [M + H] + m/z 535.1651 (calcd for [C24H33NO4 + H] + 535.1604). The
most stable conformer was deduced using molecular mechanics (MM2) energy minimization
program (ChemBio3D Ultra 12.0).

7.2.5.4. In Vitro Biological Assay

7.2.5.4.1. Antiplasmodial Assay

In vitro antiplasmodial activity was determined against D6 (chloroquine sensitive) and W2
(chloroquine resistant) strains of Plasmodium falciparum as described earlier.69

7.2.5.4.2. Phytotoxic Assay

The bioassay for phytotoxicity was carried out as described by Dayan et al.70 using bentgrass
(Agrostis stolonifera) and lettuce (Lactuca sativa cv. L., Iceberg), in 24-well plates.
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7.2.5.4.3. Cytotoxicity Assay

In vitro cytotoxicity was determined against a panel of mammalian cells as described76 earlier.
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SECTION 7.3: ANTIMALARIALS FROM A NEW ISOLATE, UM #10 M

7.3.1. Summary

Bioassay-guided fractionation of an EtOAc extract of the broth of the new fungus, UM
#10 M, isolated from a diseased T. taxifloia leaf, afforded two known cytochalasins, 19,20epoxycytochalasin C (5), 19,20-epoxycytochalasin D (6), and a new analogue, 18-deoxy-19,20epoxycytochalasin C (7). All three compounds showed potent in vitro antiplasmodial activity and
phytotoxicity with no cytotoxicity to Vero cells. These compounds were also not cytotoxic
against a panel of solid tumor cell lines (SK-MEL, KB, BT-549, and SK-OV-3) and kidney
epithelial cells (LLC-PK11). Evaluation of in vivo antimalarial activity of 19,20epoxycytochalasin C (5) in a mouse model showed that this compound was toxic to animals at
subtherapeutic doses.
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7.3.2. Introduction

Figure 7.3.1. PDA plate of the new fungus, UM #10 M

Even though this fungus was conclusively identified as a new species, 18S rDNA
analysis and morphology indicated that it most probably belongs to the family Xylariaceae.
Some members of this family have been identified192 as endophytes and plant pathogens. A
number of cytochalasins have been reported192 from Xylariaceae and several other plant
pathogenic193,

194

and endophytic192,

195, 196

ascomycete and basidiomycete genera, namely,

Penicillium, Aspergillus, Zygosporium, Phoma, Metarhizum, Rosellinia, Ascochyta, Phomopsis,
Chaetomium, Hypoxylon, and Daldinia. The chemistry and biology of cytochalasins have
extensively been studied by several research groups.192 Generally, the cytochalasin skeleton
includes a macrocyclic ring, fused with a phenylsubstituted perhydroisoindolone group.
Cytochalasins are known to be involved in fungal virulence, food spoilage, and symbiotic
fungus-host relationships.192

Cytochalasin B197,

198

and D199 have been identified as

microfilament-targeting molecules capable of blocking several cellular processes involving
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cytokinesis, intracellular motility, and cytosis,192,

200

resulting in general cytotoxicity.

Antiplasmodial57 and antitoxoplasma199 activities of cytochalasins have also been reported.
The EtOAc extract of this fungal broth showed potent antiplasmodial activity and low
cytotoxicity. Bioassay-guided fractionation yielded two known cytochalasins, 19,20epoxycytochalasin C (5),201 and 19,20-epoxycytochalasin D (6),202 and a new analogue, 18deoxy-19,20-epoxycytochalasin C (7) as active constituents.

7.3.3 Results and Discussion

Analysis of the 18S rDNA of this fungus indicated68 that it is related to both Xylariaceae
sp., and Sordariomycetes sp., with 93 % sequence homology. Morphologically, (Figure 7.3.1)
this fungus showed close similarities to Muscodor sp. of the family Xylariaceae originally
isolated from Cinnamomum zeylanicum by Strobel and coworkers.203 Since it does not show
100% homologies to all the published sequences, this fungus was designated as a new isolate,
UM # 10 M.
An EtOAc extract of the culture broth of UM # 10 M, was fractionated over silica gel,
followed by separation over Sephadex LH-20, and PTLC to afford compounds 5-7. Compounds
5201 (19,20-epoxycytochalasin C) and 6202 (19,20-epoxycytochalasin D) (Figure 7.3.2) have been
isolated from Xylaria obovata201 and X. hypoxylon,202 respectively, and were identified by
comparing their spectroscopic and physical data with reported data.
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5

6

7

Figure 7.3.2. Structure of cytochalasins (5-7)

Compound 7 was obtained as a white amorphous powder, and HRESIMS determined its
molecular formula to be C30H37NO6, one oxygen less than that of 5. Comparison of the 1H
(Figure 7.3.4) and

13

C NMR (Figure 7.3.5) resonances of 7 with those of 5 showed similarities

except for the changes observed due to the absence of the hydroxy group at C-18 (Table 7.3.1).
The 1H NMR spectrum of 7 showed a -CH3 doublet (δH 1.32) for 23-CH3 instead of a -CH3
singlet (δH 1.54) as in 5 indicating the absence of the C-18 hydroxy group. HMBC correlation
(Figures 7.3.6 and 7.3.7) of H-18 (δH 2.18) with C-20 (δC 57.6), C-19 (δC 58.6), and C-17 (δC
216.9), in combination with COSY (Figure 7.3.8) cross peaks between the C-18 methine doublet
(δH 2.18) and the C-19 oxymethine multiplet (δH 3.01) supported the gross structure of 7 to be
the 18-deoxy analogue of 5, thus named as 18-deoxy-19,20-epoxycytochalasin C (7). Relative
configuration at C-18 was assigned from ROESY correlations of 7 (Figure 7.3.9. and 7.3.10). In
the ROESY spectrum H-18 displayed interactions with H-19 indicating the cofacial orientation
of these protons. Since the analogues 5-7 presumably share a common biosynthetic origin,
compound 7 also may possess 3S, 4R, 5Z, 7S, 8R, 9R, 13E, 16S, 18S, 19R, 20S, 21S absolute
configuration.
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Figure 7.3.3. 1H NMR spectrum of 7

Figure 7.3.4.

13

C NMR spectrum of 7
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Figure 7.3.5. HMBC spectrum of 7

Figure 7.3.6.

HMBC (

) correlations of 7
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Figure 7.3.7. COSY spectrum of 7

Figure 7.3.8. ROESY spectrum of 7
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Figure 7.3.9. COSY (

) and ROESY (

) correlations of 7

Figure. 7.3.10. Gliding motility in apicomplexan parasites

Reprinted by permission from Nature Publishing Group11
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Table 7.3.1. 1H and 13C NMR data of 5-7 in CDCl3-Methanol-d4

5
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Carbon
1
3
4
5
6
7

δCb
175.0
61.0
49.9
126.4
131.8
68.1

δH a (J in Hz)

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

48.7
52.0
44.1
16.7
13.8
131.4
132.9
37.5
41.7
215.3
76.3
53.2
59.9
72.0
18.9
21.5
170.4

2.25, t (12)

3.35, m
2.50, s

3.76, d (12)

3.03, d (10)
1.19, s
1.62, s
5.5, m
5.99, dd (12, 8)
2.63, q (12), 2.14, m
3.27, s

3.38, s
3.25, m
5.75, s
1.21, d (12)
1.54, s

6
δCb
175.0
54.1
49.9
32.3
148.0
70.2

δH a (J in Hz)

46.2
53.0
44.1
13.7
113.7
131.8
132.9
37.5
41.7
215.3
76.2
59.8
53.0
72.0
18.9
21.5
170.4

2.59, m

3.28, s
2.25, m
2.53, m
3.78, d, (12.0)

2.84, d, (12.0)
13.1, d, (8.0)
5.24, bs, 5.02, bs
5.76, m
5.82, m
2.65, m
3.24, m

3.21, s
3.46, m
5.43, s
1.19, d, (6.6)
1.53, s
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7
δCb
175.1
61.1
49.9
128.5
131.7
68.1

δH a (J in Hz)

49.0
51.8
44.4
14.1
13.9
131.0
133.7
37.6
42.9
216.9
52.1
58.6
57.6
72.3
18.8
17.1
170.5

2.27, dd, (10, 10)

3.32, m
2.43, bs

3.77, d

3.04, bd, (7.5)
1.26, s
1.65, s
6.24, dd, (15.5, 10.4)
5.61, m
2.53, q (10.8), 2.14 (m)
2.98, d (1.92)
2.18, m (overlap)
3.01, m (overlap)
3.38, d (1.97)
5.69, s
1.12, d (6.7)
1.32, d (6.9)

25
1'
2',6'
3',5'
4'
a1

20.5
137.3
129.2
128.6
126.8

2.18, s
7.28, m
7.33, m
7.25, m

20.5
137.3
129.2
128.6
126.9

2.17, s
7.29, m
7.34, m
7.25, m

20.7
136.9
129.4
128.7
126.9

2.15, s
7.26, m
7.33, m
7.25, m

H NMR spectra recorded at 400 MHz, b13C NMR spectra recorded at 100 MHz
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Compounds 5-7 showed potent selective in vitro antiplasmodial activity against chloroquinesensitive (D6) and -resistant (W2) strains of P. falciparum (Table 7.3.2) and phytotoxic activity
against both a monocot (bentgrass, Agrostis stolonifera) and a dicot (lettuce, Lactuca sativa)
(Table 7.3.3). These compounds showed no cytotoxicity against a panel of solid tumor cell lines
(SK-MEL, KB, BT-549, and SK-OV-3) and kidney epithelial cells (LLC-PK11) (Table 7.3.4).
Antiplasmodial57 and antitoxoplasma199 activities of cytochalasins have been reported.
These compounds have been shown11 to inhibit the actin-based gliding motility (Figure 7.3.11)
and impair host cell invasion of apicomplexan parasites of Toxoplasma gondii199 and P.
falciparum.204
Evaluation of antimalarial activity of compound 5 in a mouse model showed that it was
toxic to mice at subtherapeutic doses (Table 7.3.5), thus precluding it as an antimalarial lead.
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7.4. Biological Activities

Table 7.3.2. Antiplasmodial activity of 5-7

Chloroquinesensitive
Compound

Chloroquine-resistant

(D6)- (W2)-clone

Cytotoxicity
to Vero cells

clone
IC50 nM

S. I.

IC50 nM

S. I.

IC50 nM

19,20-epoxycytochalasin C (5) 0.07

>129.8

0.05

>181.8

NC

19,20-epoxycytochalasin D (6) 0.04

226.7

0.04

226.7

NC

18-dehydroxy-19,20-

0.56

>7

0.19

>49.6

NC

chloroquinea

0.03

496.6

0.31

48.1

NC

artemisinina

0.02

845

0.01

1690

NC

epoxycytochalasin C (7)

a

Positive controls

NC, not cytotoxic
NA, not active
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity
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Table 7.3.3. Phytotoxic activity of 5-7

Compound

Lettuce

Bentgrass

19,20-epoxycytochalasin C (5)

3

2

19,20-epoxycytochalasin D (6)

3

3

18-dehydroxy-19,20-epoxycytochalasin C (7)

3

4

Ranking based on scale of ο to 5
0 = no effect
5 = no growth
Solvent used, 10% acetone
Concentration used, 1mg/mL

Table 7.3.4. Cytotoxic activity [IC50 (µM)] of 5-7

Compound

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

19,20-epoxycytochalasin C (5)

8.02

NA

NA

NA

NC

19,20-epoxycytochalasin D (6)

>19.1

NA

7.84

NA

8.4

epoxycytochalasin C (7)

12.41

19.7

6.89

NA

>19.7

doxorubicina

1.29

2.12

1.83

1.47

1.28

18-dehydroxy-19,20-
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NA: not active at the highest test concentration of 10 µg/mL.
a

Positive control.

IC50 = concentration casusing 50% growth inhibition
SK-MEL = human malignant melanoma
KB = human epidermal carcinoma
BT-549 = human breast carcinoma (ductal)
SK-OV-3 = human ovary carcinoma
LLC-PK11 = pig kidney epithelial

Table 7.3.5. In vivo antimalarial activity of 5

Treatment

Dose

% Parasitemia

(PO)

(mg/kg × #

suppression1

days post

Survival2

Day of

MST3

Cure4

Death

Day 5

Day 7

infection)
Vehicle

×3

-

-

0/5

13/5/13/14/14

11.8

0/5

chloroquinea

100 × 3

100

100

5/5

28/28/28/28/28

28

2/5

5

100 × 3

33.87

71.36

0/5

17/3/5/1/0

5.2

0/2
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1

% suppression in parasitemia is calculated by considering the mean parasitemia in the vehical

control as 100%.
Parasitemia suppression < 80% is considered as non-significant
2

Number of animals that survived day 28/total animals in group (the day of the death-post

infection)
3

% MST – mean survival time (days)

4

Number of mice without parasitemia (cured) till day 28 post-infection

7.5. Experimental
7.5.1. General

Carried out as previously described in Section 7.1.4.1.

7.5.2. Isolation of the Fungus from T. taxifolia

UM # 10 M was isolated as previously described in Section 7.1.5.2.

7.5.3. Fermentation, Extraction, and Purification

Fungus UM # 10 M was cultured in four conical flasks (2 L) containing 500 mL of PDB
and incubated at 27 οC for 30 days on an orbital shaker at 100 rpm. Mycelia and broth were
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separated by filtration and extracted with EtOAc (×3). The organic layer from the broth was
evaporated to give a brown/black residue (625 mg).
This extract (600 mg) was chromatogtaphed on Sephadex LH-20 and eluted with 80% MeOH in
CHCl3 to give 10 fractions. Fractions 2, 3, and 4 showed antimalarial activity. Fraction 2 was
subjected to silica gel gravity column chromatography using hexanes, CH2Cl2, and MeOH
gradient as the mobile phase to yield five fractions. Subfraction 3 which showed antimalarial
activity was further separated by preparative thin layer chromatography (PTLC) using 0.4 %
MeOH in CHCl3 (× 3) as the developing solvent to obtain 19,20-epoxycytochalasin C (5, 85.0
mg). Fractions 3 and 4 were also subjected to PTLC using 0.4 % MeOH in CHCl 3 (× 3) as the
developing solvent to afford 19,20-epoxycytochalasin D (6, 4 mg), and the new analogue, 18deoxy-19,20-epoxycytochalasin C (7, 2 mg).

Compound 5 : 19,20-Epoxycytochalasin C; white amorphous powder; 1H, 13C NMR data (Table
7.3.1) were consistent with literature values.201 [α]26D -13 (c 0.5, CHCl3) lit201 -6.8; HRESIMS
[M + H] + m/z 524.264 (lit201 [M+ H] + 524.2)

Compound 6 : 19,20-Epoxycytochalasin D; white amorphous powder; 1H, and 13C NMR, data
(Table 7.3.1) were consistent with literature values.202 [α]26D -113 (c 0.085, CHCl3) lit202 -228;
HRESIMS [M + H] + m/z 524.283 (lit202 [M+ H] + 524.2)

Compound 7 : 18-Deoxy-19,20-epoxycytochalasin C; white amorphous powder; 1H and

13

C

NMR (see Table 7.3.1.) [α]26D -2.4 (c 0.09, CHCl3); HRESIMS [M + H] + m/z 508.2703 (calcd
for [C24H33NO4 + H] + 508.2620)
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7.5.4. Biological Assay

7.5.4.1. Antiplasmodial Assay

In vitro antiplasmodial activity was determined as described earlier.69

7.5.4.2. Phytotoxic Assay

The bioassay for phytotoxicity was carried out as described70 by Dayan and coworkers.

7.5.4.3. Cytotoxicity Assay

In vitro cytotoxicity was determined against a panel of mammalian cells as described76 earlier.

7.5.4.4. In Vivo Antimalarial Assay

In vivo antimalarial activity was determined as described in Chapter 4 (4.5.7).
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SECTION 7.4: ANTIMALARIALS FROM BOTRYOSPHAERIA DOTHIDEA

7.4.1. Summary

The culture broth extract of Botryosphaeria dothidea showed antimalarial and phytotoxic
activities. Bioactivity-guided fractionation of this extract afforded a mixture of two known
phytotoxins, sapinopyridiones (8a) and flavipucine (8b), one inactive -alkyl-,-unsturated-lactam (9), and three antiplasmodial -alkyl--lactam derivatives (10-12).

7.4.2. Introduction

Botryosphaeria dothidea was isolated from seeds collected from cultivated Torreya
taxifolia trees that included plants with disease symptoms. This fungus is a member of the family
Botryosphaeriaceae (Botryosphaeriales, Ascomycetes) which includes species of telemorph and
anamorph stages of Diplodia, Botryosphaeria, Fusicoccum, Dothiorella, Lasiodiplodia, and
Sphaeropsis.205 Botryosphaeria is the teleomorph (sexual) stage of the anamorph (asexual) genus
Sphaeropsis. Chemical investigation of Sphaeropsis sapinea has been reported206 by Evidente et
al.. S. sapinea is known206 to be identical to B. dothidea. S. sapinea, also known as Diplodia
pinea, is the causative agent for shoot blight and canker diseases of pines and other conifers.208
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Several

phytotoxins,

sapinopyridione,206

sphaeropsidins,209-213

sapinofuranones,214

sphaeropsidones,215 and dimedone methyl ethers215 have been reported from S. sapinea isolated
from conifers. Most of the fungi of this family are known205 as endophytes and/or latent
pathogens and cause diseases with the onset of environmental stress factors due to climate
changes. This is the first report of the isolation of a fungus producing compounds capable of
severe plant pathogenicity from the seeds of T. taxifolia.

Figure 7.4.1. PDA plate of B. dothidea

Bioassay-guided fractionation of an EtOAc extract of the potato dextrose broth of B.
dothidea resulted in the isolation of a mixture of the known closely related phytotoxins,
sapinopyridiones (8a)206,

216

and flavipucine (8b),216,

217

and four new -alkyl --lactam

derivatives (9-12). Three of these (10-12) showed potent, selective antiplasmodial activity.
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7.4.3. Results and Discussion

Analysis68 of 18S rDNA of the fungus gave 100 % sequence identities to B. dothidea.
An EtOAc extract of B. dothidea culture broth was fractionated by silica gel column
chromatography followed by Sephadex LH-20 gel filtration (MeOH) and repeated reversedphase HPLC ( MeOH-H2O) to afford a mixture of two known phytotoxins,216 sapinopyridione
(8a) and flavipucine (8b), and four related new compounds (9-12). Structure elucidation of
sapinopyridione (8a) and flavipucine (8b) was carried out by comparing the spectroscopic data
with reported data.206, 217

Compound 9 was isolated as a brown amorphous solid, and its molecular formula was
determined as C22H29NO5 by HRESIMS. The 1H (Figure 7.4.2) and

13

C NMR (Figure 7.4.3)

spectra of 9 (Table 7.4.1) indicated the presence of 22 carbons resonances that consisted of eight
quaternary, six methine, two methylene, and six methyl carbons. Analysis of 1H and 13C NMR
data of 9 indicated that it was an α-alkyl-α,β-unsaturated-γ-lactam derivative, related to
epolactaene218 (Figure 7.4.4). Comparison of the 1H and

13

C NMR data of these compounds

showed that they had the same side chain but differed in the 2-pyrrolidone ring. These
differences were attributable to the replacement of the epoxide and the hydroxy groups in the 2pyrrolidone ring of epolactaene by a double bond and methoxy group, respectively, in 9. In the
HMBC spectrum of 9 (Figure 7.4.5), observed cross-peaks of H-1 (δH 1.72) with C-2 (δC 139.9)
and C-3 (δC 130.3); H-2 (δH 6.96) with C-3 (δC 130.3) and C-19 (δC 167.8); H-4 (δH 5.98) with
C-21 (δC 14.3), C-19 (δC 167.8), and C-2 (δC 139.9); H-21 with C-6 (δC 135.6) and C-4 (δC 112.1);
H-8 (δH 2.35) with C-6 (δC 135.6), C-7 (δC 128.2), C-9 (δC 30.1), and C-10 (δC 150.0); and H-22
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(δH 1.82) with C-10 (δC 150.0) and C-6 (δC 192.1) confirmed the structure of the side chain.
Further, HMBC correlations of the -OCH3 singlet at δH 3.18 with C-15 (δC 139.9), the 18-CH3
singlet at δH 1.61 with C-15 (δC 89.23) and C-14 (δC 149.5), and the H-14 olefinic proton singlet
at δH 6.83 with C-17 (δC 168.3) confirmed the structure of the 2-pyrrolidone moiety and its link to
the side chain. Similarly, a methyl triplet (δH 1.89) at C-22 showed correlations with C-12 (δC
191.4) and C-10 (δC 148.6), and other COSY (Figure 7.4.6) and HMBC (Figure 7.4.7)
correlations supported this structure (Figure 7.4.8). The configuration of the olefinic bond
between C-6 and C-7 was determined to be E (trans) by the coupling constant (J = 15.6 Hz). Due
to the lack of NOESY or ROESY data, the configuration of the remaining double bonds could
not been determined. However, ROESY data indicated that olifinic bonds between C-2 and C-3,
C-4 and C-5, and C-10 and C-11 in compound 10 were in E configuration (vide infra). Since
compounds 9 and 10 presumably share a common biosynthetic origin these bonds in compound 9
also have the same configurations.

182

Figure 7.4.2. 1H NMR spectrum of 9

Figure 7.4.3. 13C NMR spectrum of 9
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epolactaene

fusarin C

fusarin A

fusarin D

fusarin F

luciactaene

NG-391

PI-091

Figure 7.4.4. Structurally related compounds

Figure 7.45 Structurally reported similar compounds
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Figure 7.4.5. COSY spectrum of 9

Figure 7.4.6. HMBC spectrum of 9
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Figure 7.4.7. HMBC (

) and COSY (

) correlation of 9

The antimalarial fraction of the extract was found to be a mixture of three minor
diastereomers (10-12) which was separated by preparative HPLC. Owing to lack of sufficient
material and the apparent instability of compounds, only tentative structures could be proposed
for these compounds.
Compound 10 gave the molecular formula, C24H33NO7, by HRESIMS. Its NMR spectra
showed resonances due to the same side chain as 9, and COSY and HMBC data provided
confirmatory evidence (Figures 7.4.9–7.4.22). Comparison of the remaining resonances with
those of 9 indicated the absence of the olefinic bond and the methoxy group in the 2-pyrrolidone
ring and the presence of three oxygenated carbons due to a glycerol moiety.
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sapinopyridione (8a)

flavipucine (8b)

9

10-12

Figure 7.4.8. Structure of compounds isolated from B.dothidea
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Table 7.4.1. 1H and 13C NMR data of compounds 9-12 in CDCl3-Methanol-d4
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Epolactaene

9

10

Position

δC b

δH a (J in Hz)

δC b

δH a (J in Hz)

δC b

δH a (J in Hz)

δC b

δH a (J in Hz)

δC b

δH a (J in Hz)

1

16.0

1.72, dd, 1.2, 7.3

15.9

1.72, d, 7.1

15.8

1.55, d, 6.9

15.7

1.62, d, 7.1

15.8

1.56, d, 9.5

2

140.9

6.93, dq, 1.0, 7.3

139.9

6.93, q, 7.1

140.1

6.70, q, 10.0

140.0

6.85, q, 7.1

140.1

6.80, m

3

131.9

4

123.7

5

139.6

6

136.6

130.3
5.94, br s

123.1

130.5
5.97, br s

137.6
6.27, d, 15.6

135.6

5.77, dt, 15.6,

11

122.6

130.3
5.76, s

138.0
6.23, d, 15.6

135.0

5.68, dt, 15.2,

12

122.6

130.4
5.83,s

138.1
6.1, d, 15.6

134.9

5.60, dt, 15.4,

122.6

5.77,s

137.9
6.15, d, 15.4

134.9

6.15, d, 15.7

5.65, dt, 15.6,

7

129.7

7.8

128.2

6.6

128.8

6.9

128.7

7.2

128.8

5.56, m

8

32.6

2.35, m

31.5

2.30, m

31.6

2.20, m

31.5

2.26, m

31.5

2.20, m

9

30.1

2.47, m

28.4

2.40, m

29.4

2.30, m

29.4

2.35, m

29.4

2.30, m

10

150.0

7.01, dt, 1.0, 7.3

148.6

6.56, t, 6.4

146.4

6.59, t, 4.6

146.8

6.67, t, 6.1

147.3

6.61,m

11

137.2

137.8

138.8

137.9

137.9

12

192.1

191.4

196.2

195.9

195.2
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13

63.9

139.1

14

66.1

15

84.8

89.2

83.9

83.1

85.2

17

172.2

168.3

168.3

168.3

168.3

18

22.2

19

169.6

20

52.4

3.71, s

51.9

3.74, s

51.9

3.55, s

51.8

3.62, s

51.9

3.57, s

21

14.6

1.61, d, 1.3

14.3

1.62, s, 3.4

14.3

1.45, s

14.2

1.51, s

14.3

1.45, s

22

11.1

1.82, s

11.1

1.89, s

11.5

1.67, s

11.6

1.62, s

11.4

1.63, s

3.98, s

1.51, s

149.5

24.4

6.83, s

1.61, s

167.8

50.0

3.21, s

49.28

3.28,s

49.15

3.23,s

76.5

4.29, s

77.0

4.7, s

77.3

4.07, s

20.3

1.46, s

168.3

20.2

1.52, s

168.3

20.2

1.47, s

168.3

189

3.46, m
23

60.6

3.48, m

61.5

3.64, m

61.6

3.73, m
24

70.4

3.65, m

68.3

(overlap)

(overlap)
3.70, m

68.3

(overlap)
3.80

25

61.9
a1

3.40, d, 3.08

H NMR spectra recorded at 600 MHz. b13C NMR spectra recorded at 100 MHz.

189

61.8

3.54, m

61.8

(overlap)

Figure 7.4.9. 1H NMR spectrum of 10

Figure 7.4.10.

13

C NMR spectrum of 10
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Figure 7.4.11. COSY spectrum of 10

Figure 7.4.12. HMBC spectrum of 10
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Figure 7.4.13. ROESY spectrum of 10

Figure 7.4.14. 1H NMR spectrum of 11
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Figure 7.4.15. 13C NMR spectrum of 11

Figure 7.4.16. COSY spectrum of 11
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Figure 7.4.17. HMBC spectrum of 11

Figure 7.4.18. 1H NMR spectrum of 12
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Figure 7.4.19. 13C NMR spectrum of 12

Figure 7.4.20. COSY spectrum of 12
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Figure 7.4.21. HMBC spectrum of 12

The COSY (Figure 7.4.11) and HMBC (Figure 7.4.12) spectra of 10 showed,
respectively, two oxymethylenes (δH 3.40 and 3.48) coupled with a methine multiplet (δH 3.65)
and a methylene doublet (δH 3.40) correlating with C-23 (δC 60.6) and C-24 (δC 70.4), confirming
the presence of a glycerol moiety. In the HMBC spectrum, H-14 of the 2-pyrrolidone ring had a
cross peak with one of the oxygenated methylenes of glycerol, indicating one of its linkages.
Based on the molecular formula C24H33NO7, this compound has an additional index of
deficiency. The polarity of 10-12 was comparable to that of 9 indicating that additional hydroxy
groups were functionalized. Even though no other cross peaks between the glycerol moiety and
the 2-pyrrolidone ring were visible in the HMBC spectrum due to high noise levels, it was
probable that the second oxygenated methylene group of the former was linked to C-15 of the
latter. The tentative structure of 10 and its COSY and HMBC correlations are shown in Figure
196

7.4.22. Large coupling (J = 15.6 Hz) between H-6 and H-7 showed that the olefin bond between
C-6 and C-7 was in E (trans) configuration. ROESY correlations, as shown in the Figure 7.4.23
indicated the E configuration for the other double bonds in the side chain and cis orientation for
two cyclic rings.
HRESIMS data confirmed that compounds 11 and 12 had the same molecular formula,
C24H33NO7 as that of 10. NMR analysis showed that these compounds had identical side chains
and the same gross structure. The addition of the glycerol moiety to the 2-pyrrolidone ring
creates four stereogenic centers. Thus, these compounds 10-12 are likely diastereomeric as far as
C-13, C-14, C-15, and C-24 are concerned? However, complete structure elucidation of these
compounds was not possible due to lack of sufficient material.
Mass spectra, calculated for C21H26NO4, of compounds 10-12 had base peaks at m/z =
355.1784. This fragment could form from the parent due to the loss of glycerol as shown in the
Figure 7.4.24, further supporting the proposed structures. Compound 9 may be the biosynthetic
precursor of these compounds.

Figure 7.4.22. HMBC (

) and COSY (
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) correlations of 10

Figure 7.4.23. ROESY (

) correlations of 10

Several compounds (Figure 7.4.4) structurally related to compounds 9-12 have been
isolated and their biological activities have been studied. Epolactaene,218 isolated from
Penicillum sp. has been shown to promote neurite outgrowth and arrest the cell cycle at the
G0/G1 phase in a human neuroblastoma cell line. In addition, Osada and coworkers reported219
the ability of epolactaene to bind human Heat shock protein (Hsp60) and inhibit the Hsp60
chaperone activity that is involved in apoptosis, immunoregulatory function, and cell spreading;
however, epolataene is known220 to be labile as it contains a conjugated triene moiety and an
epoxy group which is activated by two oxo groups. Several fusarins have been isolated from
Fusarium moniliforme,221, 222 and Nectria coccinea.217 Of these compounds, fusarin C has been
identified as a mutagen, and one of the compounds responsible for the toxicity associated with F.
moniliforme has been found in contaminated food.223, 224 Luciactaene, a cell cycle inhibitor in
p53-transfected cancer cells, and NG-391 have been reported from different Fusarium sp.225 A
number of analogues of the platelet aggregation inhibitor, PI-091, isolated from Paecilomyces
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sp.,226 have been synthesized and their biological activities have been reported.219 Their
biological activity is most likely due to the presence of reactive functional groups such as α, βunsaturated carbonyl, epoxide, and hemiaminal carbonyl, which could react with biological
nucleophiles such as the sulfhydryl functionality of cysteine.219
Sapinopyridione (Figure 7.4.8) has been reported from S. sapinea, the anamorph
(asexual) genus of B. dothidea.206 (+)- and (-)-flavipucine (Figure 7.4.8) has been reported from
plant pathogenic fungi Macrophoma sp.216 and Phoma sp.217 respectively.
The fraction containing compounds 10-12 showed strong antiplasmodial activity (<1.17
nM) with no cytotoxicity to Vero cells (Table 7.4.2). The lack of material prevented further
biological studies on these compounds. However, due to instability and the toxicity reported for
this class of compounds, they would not serve as potential antimalarial agents.
Compound 9, sapinopyridione, and flavipucine were inactive in antiplasmodial assays.
The mixture of sapinopyridione and flavipucine showed weak to moderate cytotoxicity (Table
7.4.4). The mixture of sapinopyridione and flavipucine was highly phytotoxic to both monocots
and dicots (Table 7.4.3). Phytotoxic activity of sapinopyridione and flavipucine

has been

studied, and the oxirane ring and the oxo group in the aliphatic side chain have been determined
to be prerequisites for this acivity.80
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Chemical formula C24H34NO7 [M+H] +

Chemical formula C21H26NO4 [M+H] +

Exact mass m/z = 448.2335

Exact mass m/z = 356.1862

Figure 7.4.24. Mass fragmentation of compounds 10-12 and their common base peak

7.4.4. Biological Activities

Table 7.4.2. Antiplasmodial activity of 8-12

Chloroquinesensitive
Compound

Chloroquine-

Cytotoxicity

(D6)- resistant (W2)-clone to Vero cells

clone
IC50 nM

Mixture of two sapinopyridione NA
(8a) and flavipucine (8b)
NA
9
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S. I.

IC50 nM

S. I.

IC50 nM

NA

NC

NA

NC

a

10-12

<1.17

>9

<1.17

>9

NC

chloroquinea

0.03

496.6

0.31

48.1

NC

artemisinina

0.02

845

0.01

1690

NC

Positive controls

IC50 = concentration casusing 50% growth inhibition
NC, not cytotoxic
NA, not active
S. I. (selectivity index) = IC50 for cytotoxicity/IC50 for antiplasmodial activity

Table 7.4.3. Phytotoxic activity of 8-11

Compound

Lettuce

Bentgrass

(8a) and flavipucine (8b)

5

5

9

NT

NT

10-11

NT

NT

Mixture of two sapinopyridione

Ranking based on scale of ο to 5
0 = no effect
5 = no growth
Solvent used, 10% acetone
Concentration used, 1 mg/mL
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Table 7.4.4. Cytotoxic activity [IC50 (µM)] of 8-12

Compound

SK-MEL

KB

BT-549

SK-OV-3

LLC-PK11

flavipucine (8b)

5.05

21.9

20.3

6.7

7.6

9

NT

NT

NT

NT

NT

10-12

NT

NT

NT

NT

NT

doxorubicina

1.29

2.12

1.83

1.47

1.28

Mixture

of

sapinopyridione

two
(8a)

and

NA: not active at the highest test concentration of 10 µg/mL.
a

Positive control.

IC50 = concentration casusing 50% growth inhibition
SK-MEL = human malignant melanoma
KB = human epidermal carcinoma
BT-549 = human breast carcinoma (ductal)
SK-OV-3 = human ovary carcinoma
LLC-PK11 = pig kidney epithelial

7.4.5. Experimental
7.4.5.1. General
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Carried out as previously described in the section 7.1.4.1.

7.4.5.2. Isolation of the Fungus from T. taxifolia

The fungus was isolated from the infected seeds collected from a cultivated T. taxifolia
plants. Infected seeds of T. taxifolia Arnott were furnished by Dr. Edward Croom, Croomia,
1509, Smallwood Dr., Oxford, MS, and isolation of fungi from those was performed by Dr. Luis
Rosa, NCNPR, University of Mississippi.

7.4.5.3. Fermentation, Extraction, and Purification

Botryosphaeria dothidea was cultured in 80 conical flasks (1 L) containing 500 mL of
Potato Dextrose Broth and incubated at 27 οC for 14 days on an orbital shaker at 100 rpm. The
mycelium was separated by filtration, and the broth was extracted with EtOAc (× 3). The EtOAc
extract was evaporated to give a black residue (3.15 g).
The EtOAc extract (3 g) was chromatographed over silica gel and eluted with a gradient
of hexanes, CH2Cl2, and MeOH to yield 15 fractions. Fractions which showed antimalarial
activity were combined (550 mg) and chromatographed over Sephadex LH-20 and eluted with
MeOH to give 12 fractions. A white precipitate observed in subfraction 11 was separated and
washed with Et2O to yield a mixture (1:3) of sapinopyridione (8a) and flavipucine (8b).
Subfractions 6-10, which showed antimalarial activity, were combined (160 mg) and further
separated using a C18 reversed-phase semi-preparative HPLC column eluting with MeOH-H2O
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(1:4), at a flow rate of 3.0 mL/min, to give eight fractions. Sub-fraction 4, which showed no
antimalarial activity, was further purified by Sephadex LH-20 gel filtration with MeOH (100%)
to give a new compound (9, < 1.5 mg).
Subfractions 5-7, which showed potent antimalarial activity, were further purified by
using C18 reversed-phase analytical HPLC chromatography and eluted with MeOH-H2O (1:4) at
a flow rate of 1.5 mL/min, to give three minor compounds 10 (1.0 mg), 11 (1.0 mg), and 12
(<1.0mg).

A mixture (1:3) of sapinopyridione (8a) and flavipucin (8b); white amorphous powder; 1H and
13

C NMR, and HRESIMS were compared with the literature data.206, 217

Compound 9: epolactaene; HRESIMS [M + H] + m/z 388.2184 (calcd for [C24H33NO4 + H] +
388.2124), 1H and 13C NMR data: see Table 7.4.1

Compound 10: HRESIMS [M + H] + m/z 448.2268 (calcd for [C24H33NO4 + H] + 448.2335), 1H
and 13C NMR data: see Table 7.4.1

Compound 11: HRESIMS [M + H] + m/z 448.2268 (calcd for [C24H33NO4 + H] + 448.2335), 1H
and 13C NMR data: please see Table 7.4.1

Compound 12: HRESIMS [M + H] + m/z 448.2247 (calcd for [C24H33NO4 + H] + 448.2335), 1H
and 13C NMR data: see Table 7.4.1
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7.4.5.4. Biological Assay
Antiplasmodial,69 phytotoxic,70 and cytotoxicity76 assays were carried out as previously
described.
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